ID,Inclusion_Exlusion,PFS_Paper,Final_judge_PFS,ORR_Paper,Final_judge_ORR,Blinding_Central,Trial_phase,Trial_number,Trial_name,Tumor_pre,Tumor,Funding,Industry_name,Trial_arm,Treatment_line,Treatment_line_re,Drug_name_intervention,Drug_classification_intervention,Drug_name_control,Drug_classification_control,Primary_outcome,Response_criteria,Randomized_patient_number_intervention,Randomized_patient_number_control,Follow_up_period_months_median,PFS_INV_HR,PFS_INV_95%CI_lower,PFS_INV_95%CI_upper,PFS_CNT_HR,PFS_CNT_95%CI_lower,PFS_CNT_95%CI_upper,ORR_N_INV_intervention,CR+PR_INV_intervention,ORR_N_INV_control,CR+PR_INV_control,ORR_N_CNT_intervention,CR+PR_CNT_intervention,ORR_N_CNT_control,CR+PR_CNT_control,Median_OS_intervention,Median_OS_control,OS_HR,OS_95%CI_lower,OS_95%CI_upper,title,journal,IF_2021,year,Authors,authors,url,pubmed_id,PFS_SE_INT,PFS_SE_CNT,RHR,lnRHR,lnRHR_SE_p_0,lnRHR_SE_p_0.25,lnRHR_SE_p_0.5,lnRHR_SE_p_0.75,lnRHR_SE_p_0.95,ORR_INT,ORR_INV_95%CI_lower,ORR_INV_95%CI_upper,ORR_CENT,ORR_CNT_95%CI_lower,ORR_CNT_95%CI_upper,ORR_SE_INT,ORR_SE_CNT,ROR,lnROR,lnROR_SE_p_0,lnROR_SE_p_0.25,lnROR_SE_p_0.5,lnROR_SE_p_0.75,lnROR_SE_p_0.95
4,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02574455,ASCENT,Breast cancer,Breast cancer,Industry,Immunomedics,2,≥3,≥3,Sacituzumab Govitecan,Target therapy,"eribulin, vinorelbine, capecitabine, and gemcitabine",Chemotherapy,PFS,RECIST 1.1,267,262,17.7,0.35,0.28,0.44,0.41,0.32,0.52,235,80,233,15,235,82,233,11,12.1,6.7,0.48,0.38,0.59,Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.,The New England journal of medicine,176.08,2021,Bardia A and Hurvitz SA and Tolaney SM and Loirat D and Punie K and Oliveira M and Brufsky A and Sardesai SD and Kalinsky K and Zelnak AB and Weaver R and Traina T and Dalenc F and Aftimos P and Lynce F and Diab S and Cortﾃｩs J and O'Shaughnessy J and Diﾃｩras V and Ferrario C and Schmid P and Carey LA and Gianni L and Piccart MJ and Loibl S and Goldenberg DM and Hong Q and Olivo MS and Itri LM and Rugo HS,Bardia,https://pubmed.ncbi.nlm.nih.gov/33882206/,33882206,0.040816327,0.051020408,0.853658537,-0.158224005,0.169217164,0.146608729,0.119807304,0.084932096,0.038745291,7.501075269,4.16358163,13.51387704,10.81639929,5.578229935,20.97340821,2.385279441,3.927341398,0.693490973,-0.366017056,0.452050993,0.391936654,0.320746912,0.228348028,0.10749053
11,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02631876,FORWARD I,Ovarian cancer,Ovarian cancer,Industry,ImmunoGen,2,≥2,≥2,mirvetuximab soravtansine,Target therapy,Investigator choice,Chemotherapy,PFS,RECIST 1.1,248,118,12.5,0.809,0.680738384,0.961428083,0.981,0.73,1.31,248,72,118,19,248,55,118,14,16.4,14,0.815,0.58,1.15,"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primaryﾂanalysis of FORWARD I.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2021,Moore KN and Oza AM and Colombo N and Oaknin A and Scambia G and Lorusso D and Konecny GE and Banerjee S and Murphy CG and Tanyi JL and Hirte H and Konner JA and Lim PC and Prasad-Hayes M and Monk BJ and Pautier P and Wang J and Berkenblit A and Vergote I and Birrer MJ,Moore,https://pubmed.ncbi.nlm.nih.gov/33667670/,33667670,0.071604515,0.147959184,0.824668705,-0.192773543,0.173227288,0.153097842,0.129885354,0.101496114,0.071038481,2.131578947,1.21478535,3.74027297,2.116950407,1.123736828,3.988014732,0.644257046,0.730683139,1.006910195,0.006886429,0.432100009,0.37464792,0.306613292,0.218317103,0.1028731
14,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT02811861,CLEAR,Renal cell cancer,Renal cell cancer,Industry,Eisai and Merck Sharp and Dohme,3,1,1,Lenvatinib plus Pembrolizumab,Immune checkpoint inhibitor and target therapy,Sunitinib,Target therapy,PFS,RECIST 1.1,355,357,26.6,0.47,0.38,0.58,0.39,0.32,0.49,355,244,357,122,355,252,357,129,Not reached,Not reached,0.66,0.49,0.88,Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.,The New England journal of medicine,176.08,2021,Motzer R and Alekseev B and Rha SY and Porta C and Eto M and Powles T and Grﾃｼnwald V and Hutson TE and Kopyltsov E and Mﾃｩndez-Vidal MJ and Kozlov V and Alyasova A and Hong SH and Kapoor A and Alonso Gordoa T and Merchan JR and Winquist E and Maroto P and Goh JC and Kim M and Gurney H and Patel V and Peer A and Procopio G and Takagi T and Melichar B and Rolland F and De Giorgi U and Wong S and Bedke J and Schmidinger M and Dutcus CE and Smith AD and Dutta L and Mody K and Perini RF and Xing D and Choueiri TK,Motzer,https://pubmed.ncbi.nlm.nih.gov/33616314/,33616314,0.051020408,0.043367347,1.205128205,0.186585956,0.15313685,0.132621041,0.10828567,0.076571745,0.034251843,4.234234234,3.095195916,5.792440943,4.324226688,3.156045577,5.924799243,0.688072711,0.706314711,0.979188775,-0.02103083,0.226659006,0.196292861,0.160273111,0.113331605,0.050688448
15,Inclusion,Investigator + Central,Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT01630083,FAST,Gastric and Gastroesophageal Junction Adenocarcinoma,Gastric and gastroesophageal junction cancer,Industry,Astellas Pharma,3,1,1,Zolbetuximab (IMAB362) plus EOX 600/800,Target therapy and chemotherapy,"EOX (epirubicin, oxaliplatin, capecitabine)",Chemotherapy,PFS,RECIST 1.1,77,84,NA,NA,NA,NA,0.44,0.29,0.67,77,29,84,22,77,30,84,21,13.0,8.3,0.55,0.39,0.77,FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2021,Sahin U and Tﾃｼreci ﾃ and Manikhas G and Lordick F and Rusyn A and Vynnychenko I and Dudov A and Bazin I and Bondarenko I and Melichar B and Dhaene K and Wiechen K and Huber C and Maurus D and Arozullah A and Park JW and Schuler M and Al-Batran SE,Sahin,https://pubmed.ncbi.nlm.nih.gov/33610734/,33610734,#VALUE!,0.096938776,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.702651515,0.871143219,3.32783648,1.914893617,0.97637265,3.755551291,0.626707465,0.708974143,0.889162458,-0.117475318,0.4847697,0.419823791,0.342786185,0.242389609,0.108411277
18,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT03080805,PHOEBE,Breast cancer,Breast cancer,Industry and Public,Jiangsu Hengrui Medicine and National Key R&D Program of China.,2,"1, 2, 3",≥1,Pyrotinib plus capecitabine,Target therapy and chemotherapy,lapatinib plus capecitabine,Target therapy and chemotherapy,PFS,RECIST 1.1,134,133,21.8/21.5,0.42,0.3,0.6,0.39,0.27,0.56,134,93,132,60,134,90,132,68,26.8,Not reached,In progress,In progress,In progress,"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.",The Lancet. Oncology,54.43,2021,Xu B and Yan M and Ma F and Hu X and Feng J and Ouyang Q and Tong Z and Li H and Zhang Q and Sun T and Wang X and Yin Y and Cheng Y and Li W and Gu Y and Chen Q and Liu J and Cheng J and Geng C and Qin S and Wang S and Lu J and Shen K and Liu Q and Wang X and Wang H and Luo T and Yang J and Wu Y and Yu Z and Zhu X and Chen C and Zou J,Xu,https://pubmed.ncbi.nlm.nih.gov/33581774/,33581774,0.076530612,0.073979592,1.076923077,0.074107972,0.256709843,0.222365635,0.181639774,0.12860614,0.058109938,2.72195122,1.64701959,4.49843978,1.92513369,1.171746076,3.162920534,0.72740311,0.507952668,1.413902439,0.346353569,0.360371688,0.312094643,0.254830098,0.180204582,0.080634616
22,Inclusion,Investigator + Central,Investigator + Central,Unclear,Central,Blinding,Phase 3,"NCT01802749, EudraCT 2012-004362-17",MITO16b/MANGO–OV2/ENGOT–ov17,Ovarian cancer,Ovarian cancer,Industry and Public,Hoffmann–La Roche and Associazione Italiana per la Ricerca sul Cancro.,2,2,2,carboplatin-based doublet plus bevacizumab,Target therapy and chemotherapy,carboplatin-based doublet,Chemotherapy,PFS,RECIST 1.1,203,203,20.1,0.51,0.41,0.65,0.52,0.42,0.66,NA,NA,NA,NA,130,90,143,71,26.7,27.1,0.99,0.73,1.39,"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.",The Lancet. Oncology,54.43,2021,Pignata S and Lorusso D and Joly F and Gallo C and Colombo N and Sessa C and Bamias A and Salutari V and Selle F and Frezzini S and De Giorgi U and Pautier P and Bologna A and Orditura M and Dubot C and Gadducci A and Mammoliti S and Ray-Coquard I and Zafarana E and Breda E and Favier L and Ardizzoia A and Cinieri S and Largillier R and Sambataro D and Guardiola E and Lauria R and Pisano C and Raspagliesi F and Scambia G and Daniele G and Perrone F,Pignata,https://pubmed.ncbi.nlm.nih.gov/33539744/,33539744,0.06122449,0.06122449,0.980769231,-0.019418086,0.164662628,0.142606466,0.116444955,0.082354422,0.036885084,#VALUE!,#VALUE!,#VALUE!,2.281690141,1.389222262,3.747499621,#VALUE!,0.601601367,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
23,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NTR4132/NL3847,NVALT19,Malignant mesothelioma,Malignant mesothelioma,Public,Dutch Cancer Society and Stichting NVALT studies,2,2,2,Gemcitabine plus supportive care,Chemotherapy,supportive care,BSC,PFS,mRECIST,65,65,36.5,0.48,0.33,0.71,0.49,0.33,0.72,48,8,50,2,46,5,46,1,16.4,13.4,0.9,0.6,1.34,"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.",The Lancet. Respiratory medicine,54.43,2021,de Gooijer CJ and van der Noort V and Stigt JA and Baas P and Biesma B and Cornelissen R and van Walree N and van Heemst RC and Soud MY and Groen HJM and den Brekel AJS and Buikhuisen WA and Bootsma GP and Dammeijer F and van Tinteren H and Lalezari F and Aerts JG and Burgers JA,de,https://pubmed.ncbi.nlm.nih.gov/33515500/,33515500,0.096938776,0.099489796,0.979591837,-0.020619287,0.27894535,0.241580346,0.197260283,0.139506898,0.062470945,4.8,0.963955032,23.90152987,5.487804878,0.615175944,48.95510407,5.851422153,12.33161432,0.874666667,-0.133912418,1.384718672,1.208390261,1.001483023,0.738735047,0.424191522
31,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT03134872,CameL,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Jiangsu Hengrui Medicine,2,1,1,Camrelizumab plus carboplatin and pemetrexed,Immune checkpoint inhibitor and chemotherapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,209,210,11.9 (interim analysis),0.54,0.42,0.69,0.6,0.45,0.79,205,111,207,65,205,124,207,80,Not reached,20.9,0.73,0.53,1.02,"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.",The Lancet. Respiratory medicine,54.43,2021,Zhou C and Chen G and Huang Y and Zhou J and Lin L and Feng J and Wang Z and Shu Y and Shi J and Hu Y and Wang Q and Cheng Y and Wu F and Chen J and Lin X and Wang Y and Huang J and Cui J and Cao L and Liu Y and Zhang Y and Pan Y and Zhao J and Wang L and Chang J and Chen Q and Ren X and Zhang W and Fan Y and He Z and Fang J and Gu K and Dong X and Zhang T and Shi W and Zou J,Zhou,https://pubmed.ncbi.nlm.nih.gov/33347829/,33347829,0.068877551,0.086734694,0.9,-0.105360516,0.191441623,0.166009158,0.135897704,0.096836623,0.045876442,2.579705401,1.725712815,3.856307897,2.430246914,1.635860362,3.610393772,0.543519153,0.503707503,1.061499301,0.059682344,0.287851327,0.249291597,0.203553959,0.143951826,0.064439577
34,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT03273153,IMspire170,Melanoma,Melanoma,Industry,Hoffmann-La Roche and Genentech Inc,2,1,1,cobimetinib plus atezolizumab,Immune checkpoint inhibitor and target therapy,Pembrolizmab,Immune checkpoint inhibitor,PFS,RECIST 1.1,222,224,7.1/7.2,1.32,1.02,1.71,1.15,0.88,1.5,222,62,221,81,204,53,206,65,Not reached,Not reached,1.06,0.69,1.61,Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2021,Gogas H and Drﾃｩno B and Larkin J and Demidov L and Stroyakovskiy D and Eroglu Z and Francesco Ferrucci P and Pigozzo J and Rutkowski P and Mackiewicz J and Rooney I and Voulgari A and Troutman S and Pitcher B and Guo Y and Yan Y and Castro M and Mulla S and Flaherty K and Arance A,Gogas,https://pubmed.ncbi.nlm.nih.gov/33309774/,33309774,0.176020408,0.158163265,1.147826087,0.137869794,0.189425349,0.164060841,0.133977446,0.094783715,0.042557608,0.669753086,0.448479253,1.000200552,0.761385634,0.495650968,1.16958933,0.140745229,0.171923051,0.87965028,-0.128230859,0.299724579,0.259668919,0.212181695,0.150380172,0.068474049
41,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT03052608,CROWN,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Pfizer,2,1,1,Lorlatinib,Target therapy,Crizotinib,Target therapy,PFS,RECIST 1.1,149,147,18.3/14/8,0.21,0.14,0.31,0.28,0.19,0.41,149,120,147,91,149,113,147,85,NA,NA,0.72,0.41,1.25,First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.,The New England journal of medicine,176.08,2020,Shaw AT and Bauer TM and de Marinis F and Felip E and Goto Y and Liu G and Mazieres J and Kim DW and Mok T and Polli A and Thurm H and Calella AM and Peltz G and Solomon BJ,Shaw,https://pubmed.ncbi.nlm.nih.gov/33207094/,33207094,0.043367347,0.056122449,0.75,-0.287682072,0.282170905,0.244389323,0.199579215,0.141200514,0.063420523,2.546419098,1.506817664,4.303274628,2.289542484,1.391653258,3.766746318,0.713381879,0.605891087,1.11219561,0.106336088,0.369030242,0.319662838,0.26112323,0.184895517,0.083589239
47,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT02667743,No name,Non-small cell lung cancer,Non-small cell lung cancer,Industry,"Shanghai Yizhong Biotechnical
Co., Ltd.",2,1,1,Polymeric micellar paclitaxel plus cisplatin,Chemotherapy,Solvent-based paclitaxel plus cisplatin,Chemotherapy,ORR,RECIST 1.1,302,152,NA,0.66,0.52,0.84,0.63,0.5,0.8,300,156,148,42,300,151,148,39,18,16.4,0.84,0.65,1.08,"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2021,Shi M and Gu A and Tu H and Huang C and Wang H and Yu Z and Wang X and Cao L and Shu Y and Wang H and Yang R and Li X and Chang J and Hu Y and Shen P and Hu Y and Guo Z and Tao M and Zhang Y and Liu X and Sun Q and Zhang X and Jiang Z and Zhao J and Chen F and Yu H and Zhang W and Sun J and Li D and Zhou J and Han B and Wu YL,Shi,https://pubmed.ncbi.nlm.nih.gov/33130217/,33130217,0.081632653,0.076530612,1.047619048,0.046520016,0.171297506,0.148353014,0.121137928,0.085674842,0.038377118,2.734126984,1.790893334,4.174146065,2.832386853,1.842343006,4.35446345,0.607972635,0.640847052,0.965308458,-0.035307583,0.307810738,0.266577872,0.217669643,0.153936303,0.068916142
72,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01849874,MILO,Ovarian cancer,Ovarian cancer,Industry and Public,"Pfizer, NIH, Memorial Sloan Kettering Cancer Center Support Grant, Ovarian Cancer Research Fund",2,"2, 3, 4",≥2,Binimetinib,Target therapy,Investigator choice,Chemotherapy,PFS,RECIST 1.1,201,102,NA,0.87,0.56,1.34,1.21,0.79,1.86,198,35,101,13,198,32,101,13,25.33,20.83,0.85,0.49,1.48,"MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2020,Monk BJ and Grisham RN and Banerjee S and Kalbacher E and Mirza MR and Romero I and Vuylsteke P and Coleman RL and Hilpert F and Oza AM and Westermann A and Oehler MK and Pignata S and Aghajanian C and Colombo N and Drill E and Cibula D and Moore KN and Christy-Bittel J and Del Campo JM and Berger R and Marth C and Sehouli J and O'Malley DM and Churruca C and Boyd AP and Kristensen G and Clamp A and Ray-Coquard I and Vergote I,Monk,https://pubmed.ncbi.nlm.nih.gov/32822286/,32822286,0.198979592,0.272959184,0.719008264,-0.329882427,0.311859837,0.270086435,0.220537541,0.155970932,0.069850063,1.453515809,0.730961852,2.890312542,1.304911956,0.651562588,2.61340237,0.550854768,0.500469332,1.113880368,0.107849746,0.498551824,0.431762384,0.352538781,0.249295864,0.111536075
73,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT02737501,ALTA-1L,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Ariad Pharmaceuticals,2,≥1,≥1,Brigatinib,Target therapy,Crizotinib,Target therapy,PFS,RECIST 1.1,137,138,24.9/15.2,0.43,0.31,0.61,0.49,0.35,0.68,NA,NA,NA,NA,137,101,138,85,NA,NA,0.92,0.57,1.47,Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2020,Camidge DR and Kim HR and Ahn MJ and Yang JCH and Han JY and Hochmair MJ and Lee KH and Delmonte A and Garcﾃｭa Campelo MR and Kim DW and Griesinger F and Felip E and Califano R and Spira A and Gettinger SN and Tiseo M and Lin HM and Gupta N and Hanley MJ and Ni Q and Zhang P and Popat S,Camidge,https://pubmed.ncbi.nlm.nih.gov/32780660/,32780660,0.076530612,0.084183673,0.87755102,-0.130620182,0.241914703,0.209510568,0.171074932,0.120990027,0.054186254,#VALUE!,#VALUE!,#VALUE!,1.749346405,1.04808829,2.919804442,#VALUE!,0.47747861,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
98,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,Eudra-CT 2016-001604-28,INSIGHT,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Merck KGaA,2,≥2,≥2,Tepotinib plus gefitinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,31,24,21.8?,0.67,0.35 (90%CI),1.28 (90%CI),0.51,0.23 (95%CI),1.14 (95%CI),31,14,24,8,31,12,24,10,17.3,18.7,0.69,0.34 (90%CI),1.41 (90%CI),"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.",The Lancet. Respiratory medicine,54.43,2020,Wu YL and Cheng Y and Zhou J and Lu S and Zhang Y and Zhao J and Kim DW and Soo RA and Kim SW and Pan H and Chen YM and Chian CF and Liu X and Tan DSW and Bruns R and Straub J and Johne A and Scheele J and Park K and Yang JC,Wu,https://pubmed.ncbi.nlm.nih.gov/32479794/,32479794,0.281818182,0.275757576,1.31372549,0.272866987,0.566693097,0.49083109,0.400860637,0.283660612,0.127603355,1.647058824,0.545609851,4.972056063,0.884210526,0.298273505,2.621179023,1.129195462,0.592577938,1.862745098,0.622051259,0.790661485,0.6847486,0.559120475,0.395412147,0.177027723
106,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT03434379,IMbrave150,Hepatocellular cancer,Hepatocellular cancer,Industry,Hoffmann–La Roche/Genentech,2,1,1,Atezolizumab plus Bevacizumab,Immune checkpoint inhibitor and target therapy,Sorafenib,Target therapy,OS and PFS,RECIST 1.1,336,165,8.6,0.45,0.36,0.57,0.59,0.47,0.76,336,86,165,9,326,89,159,19,Not reached,13.2,0.58,0.42,0.79,Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.,The New England journal of medicine,176.08,2020,Finn RS and Qin S and Ikeda M and Galle PR and Ducreux M and Kim TY and Kudo M and Breder V and Merle P and Kaseb AO and Li D and Verret W and Xu DZ and Hernandez S and Liu J and Huang C and Mulla S and Wang Y and Lim HY and Zhu AX and Cheng AL,Finn,https://pubmed.ncbi.nlm.nih.gov/32402160/,32402160,0.053571429,0.073979592,0.762711864,-0.270874954,0.169625136,0.14692422,0.120003191,0.084940011,0.038288866,5.962666667,2.916315939,12.191201,2.767044193,1.616381266,4.736836367,2.366042106,0.796034464,2.154886677,0.767738136,0.456485569,0.397915957,0.329082275,0.241356951,0.134980017
114,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT02675231,monarcHER,Breast cancer,Breast cancer,Industry,Eli Lilly,3,≥3,≥3,abemaciclib plus trastuzumab plus fulvestrant,Target therapy and Hormone therapy,trastuzumab plus standard of care chemotherapy,Hormone therapy and Chemotherapy,PFS,RECIST 1.1,79,79,19,0.673,0.45,1,0.883,0.565,1.368,79,26,79,11,79,24,79,9,In progress,In progress,In progress,In progress,In progress,"Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.",The Lancet. Oncology,54.43,2020,Tolaney SM and Wardley AM and Zambelli S and Hilton JF and Troso-Sandoval TA and Ricci F and Im SA and Kim SB and Johnston SR and Chan A and Goel S and Catron K and Chapman SC and Price GL and Yang Z and Gainford MC and Andrﾃｩ F,Tolaney,https://pubmed.ncbi.nlm.nih.gov/32353342/,32353342,0.140306122,0.204846939,0.762174405,-0.271579871,0.303942551,0.263449227,0.215476022,0.153148088,0.071231126,3.032590051,1.374700755,6.689894063,3.393939394,1.459953653,7.889856356,1.35591666,1.640281302,0.893530997,-0.112574253,0.590076051,0.511195691,0.4176749,0.295945282,0.134494015
120,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Unclear,Phase 3,NCT02367794,IMpower131,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Hoffmann-La Roche/Genentech,3,1,1,Atezolizumab plus carboplatin plus nab-paclitaxel,Immune checkpoint inhibitor and chemotherapy,carboplatin plus nab-paclitaxel,Chemotherapy,PFS,RECIST 1.1,343,340,18.1/16.1,0.71,0.6,0.85,0.8,0.67,0.96,342,170,339,139,NA,NA,NA,NA,14.2,13.5,0.88,0.73,1.05,Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized PhaseﾂIII Trial.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,20.12,2020,Jotte R and Cappuzzo F and Vynnychenko I and Stroyakovskiy D and Rodrﾃｭguez-Abreu D and Hussein M and Soo R and Conter HJ and Kozuki T and Huang KC and Graupner V and Sun SW and Hoang T and Jessop H and McCleland M and Ballinger M and Sandler A and Socinski MA,Jotte,https://pubmed.ncbi.nlm.nih.gov/32302702/,32302702,0.06377551,0.073979592,0.8875,-0.119346758,0.127721744,0.110619747,0.09033611,0.063910072,0.028698516,1.422118119,1.050428998,1.925327603,#VALUE!,#VALUE!,#VALUE!,0.22318842,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
125,Inclusion,Unclear,Invesitigator,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT02574598,PROLUNG,Non-small cell lung cancer,Non-small cell lung cancer,Industry,merck sharp & dohme,3,2,2,Pembrolizumab Plus Docetaxel,Immune checkpoint inhibitor and chemotherapy,Docetaxel,Chemotherapy,ORR,RECIST 1.1,40,38,8.9/7/9,NA,NA,NA,0.24,0.13,0.46,40,23,38,11,40,17,38,6,14.6,14.1,1.19,0.62,2.26,Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.,JAMA oncology,33.01,2020,Arrieta O and Barrﾃｳn F and Ramﾃｭrez-Tirado LA and Zatarain-Barrﾃｳn ZL and Cardona AF and Dﾃｭaz-Garcﾃｭa D and Yamamoto Ramos M and Mota-Vega B and Carmona A and Peralta ﾃ〕varez MP and Bautista Y and Aldaco F and Gerson R and Rolfo C and Rosell R,Arrieta,https://pubmed.ncbi.nlm.nih.gov/32271354/,32271354,#VALUE!,0.084183673,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,3.320855615,1.296583874,8.505490648,3.942028986,1.346850025,11.53773044,1.83900683,2.59971439,0.842422932,-0.171473097,0.728331226,0.631671209,0.517252992,0.368907574,0.17585935
138,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02282020,SOLO3,Ovarian cancer,Ovarian cancer,Industry,"between AstraZeneca and Merck Sharp &
Dohme Corp (MSD)",2,≥3,≥3,Olaparib,Target therapy,Chemotherapy,Chemotherapy,ORR,RECIST 1.1,178,88,NA,0.49,0.35,0.7,0.62,0.43,0.91,151,99,72,29,160,92,78,25,In progress,In progress,In progress,In progress,In progress,Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2020,Penson RT and Valencia RV and Cibula D and Colombo N and Leath CA 3rd and Bidziﾅгki M and Kim JW and Nam JH and Madry R and Hernﾃ｡ndez C and Mora PAR and Ryu SY and Milenkova T and Lowe ES and Barker L and Scambia G,Penson,https://pubmed.ncbi.nlm.nih.gov/32073956/,32073956,0.089285714,0.12244898,0.790322581,-0.235314087,0.260459336,0.225679545,0.184454463,0.130826757,0.059911549,2.822944297,1.583170966,5.033577975,2.868235294,1.622775219,5.0695707,0.88020587,0.879284561,0.984209456,-0.015916543,0.414142154,0.358664638,0.292859901,0.207107509,0.092708141
161,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Blinding,Phase 3,NCT02627963,TIVO-3,Renal cell cancer,Renal cell cancer,Industry,AVEO Oncology,2,"3, 4",≥3,Tivozanib,Target therapy,Sorafenib,Target therapy,PFS,RECIST 1.1,175,175,19,0.62,0.48,0.8,0.73,0.56,0.94,NA,NA,NA,NA,175,31,175,14,16.4,19.7,0.99,0.76,1.29,"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.",The Lancet. Oncology,54.43,2020,Rini BI and Pal SK and Escudier BJ and Atkins MB and Hutson TE and Porta C and Verzoni E and Needle MN and McDermott DF,Rini,https://pubmed.ncbi.nlm.nih.gov/31810797/,31810797,0.081632653,0.096938776,0.849315068,-0.163325056,0.185578251,0.160718044,0.13122992,0.092802448,0.041534278,#VALUE!,#VALUE!,#VALUE!,2.475694444,1.26687074,4.83795449,#VALUE!,0.910990753,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
186,Inclusion,Investigator + Central,Invesitigator,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT01328171,AIO KRKO109,Colorectal cancer,Colorectal cancer,Industry and Public,"Arbeitsgemeinschaft Internistische Onkologie (AIO) Studien (Berlin, Germany) and Amgen",2,1,1,mFOLFOXIRI plus panitumumab,Target therapy and chemotherapy,FOLFOXIRI,Chemotherapy,ORR,RECIST 1.1,71,34,44.2/63.3,1.07,0.69,1.67,NA,NA,NA,63,55,33,20,56,50,30,20,35.7,27,0.67,0.41,1.11,"FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2019,Modest DP and Martens UM and Riera-Knorrenschild J and Greeve J and Florschﾃｼtz A and Wessendorf S and Ettrich T and Kanzler S and Nﾃｶrenberg D and Ricke J and Seidensticker M and Held S and Buechner-Steudel P and Atzpodien J and Heinemann V and Seufferlein T and Tannapfel A and Reinacher-Schick AC and Geissler M,Modest,https://pubmed.ncbi.nlm.nih.gov/31609637/,31609637,0.25,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,4.46875,1.613595693,12.37591712,4.166666667,1.336248245,12.99242949,2.74549016,2.973515624,1.0725,0.069992372,0.77895543,0.675273387,0.552464237,0.392987683,0.183895044
193,Inclusion,Central,Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02928224,BEACON CRC,Colorectal cancer,Colorectal cancer,Industry,Array BioPharma and others,3,"2, 3",≥2,"Triplet Regimen (encorafenib, binimetinib and cetuximab)",Target therapy,investigators’ choice,Target therapy or chemotherapy,OS and ORR,RECIST 1.1,224,221,7.8,NA,NA,NA,0.38,0.29,0.49,111,29,107,4,111,29,107,2,9,5.4,0.52,0.39,0.7,"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.",The New England journal of medicine,176.08,2019,Kopetz S and Grothey A and Yaeger R and Van Cutsem E and Desai J and Yoshino T and Wasan H and Ciardiello F and Loupakis F and Hong YS and Steeghs N and Guren TK and Arkenau HT and Garcia-Alfonso P and Pfeiffer P and Orlov S and Lonardi S and Elez E and Kim TW and Schellens JHM and Guo C and Krishnan A and Dekervel J and Morris V and Calvo Ferrandiz A and Tarpgaard LS and Braun M and Gollerkeri A and Keir C and Maharry K and Pickard M and Christy-Bittel J and Anderson L and Sandor V and Tabernero J,Kopetz,https://pubmed.ncbi.nlm.nih.gov/31566309/,31566309,#VALUE!,0.051020408,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,9.106707317,3.077470721,26.94814206,18.56707317,4.304421331,80.08886203,6.089456973,19.33276548,0.49047619,-0.712378542,0.928756324,0.810051177,0.670654539,0.49332759,0.279728068
226,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator,Blinding,Phase 3,NCT02367781,IMpower130,Non-small cell lung cancer,Non-small cell lung cancer,Industry,F. Hoffmann-La Roche,2,1,1,"Atezolizumab, carboplatin plus nab-paclitaxel",Immune checkpoint inhibitor and chemotherapy,Chemotherapy,Chemotherapy,OS and PFS,RECIST 1.1,483,240,18.5/19.2,0.65,0.54,0.77,0.75,0.63,0.91,447,220,226,72,NA,NA,NA,NA,18.1,13.9,0.8,0.65,0.99,"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.",The Lancet. Oncology,54.43,2019,West H and McCleod M and Hussein M and Morabito A and Rittmeyer A and Conter HJ and Kopp HG and Daniel D and McCune S and Mekhail T and Zer A and Reinmuth N and Sadiq A and Sandler A and Lin W and Ochi Lohmann T and Archer V and Wang L and Kowanetz M and Cappuzzo F,West,https://pubmed.ncbi.nlm.nih.gov/31122901/,31122901,0.058673469,0.071428571,0.866666667,-0.143100844,0.130356824,0.112904318,0.092205577,0.065240722,0.029324708,2.072931963,1.481827903,2.899828593,#VALUE!,#VALUE!,#VALUE!,0.36173487,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
233,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT02420821,IMmotion151,Renal cell cancer,Renal cell cancer,Industry,F Hoffmann–La Roche Ltd and Genentech Inc,2,1,1,Atezolizumab plus bevacizumab,Immune checkpoint inhibitor and target therapy,Sunitinib,Target therapy,OS and PFS,RECIST 1.1,454,461,24,0.83,0.7,0.97,0.88,0.74,1.04,454,166,460,153,454,151,460,144,33.6,34.9,0.93,0.76,1.14,"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.","Lancet (London, England)",202.73,2019,Rini BI and Powles T and Atkins MB and Escudier B and McDermott DF and Suarez C and Bracarda S and Stadler WM and Donskov F and Lee JL and Hawkins R and Ravaud A and Alekseev B and Staehler M and Uemura M and De Giorgi U and Mellado B and Porta C and Melichar B and Gurney H and Bedke J and Choueiri TK and Parnis F and Khaznadar T and Thobhani A and Li S and Piault-Louis E and Frantz G and Huseni M and Schiff C and Green MC and Motzer RJ,Rini,https://pubmed.ncbi.nlm.nih.gov/31079938/,31079938,0.068877551,0.076530612,0.943181818,-0.058496207,0.120260622,0.104164303,0.085075183,0.060211059,0.027118988,1.156545025,0.880926256,1.518397694,1.093601027,0.828672281,1.443228202,0.162620265,0.15677447,1.057556638,0.055961189,0.198296352,0.171734778,0.140229187,0.099174672,0.044415403
246,Inclusion,Investigator + Central,Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01655693,RELIVE,Hepatocellular cancer,Hepatocellular cancer,Industry,Onxeo,3,≥2,≥2,doxorubicin-loaded nanoparticles,Chemotherapy,Standard care,Standard care,OS,RECIST 1.1,263,134,22.7,appendix p9,appendix p9,appendix p9,0.95,0.74,1.22,219,6,78,4,204,2,72,1,9.1,9,1,0.78,1.28,Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.,The lancet. Gastroenterology & hepatology,45.04,2019,Merle P and Blanc JF and Phelip JM and Pelletier G and Bronowicki JP and Touchefeu Y and Pageaux G and Gerolami R and Habersetzer F and Nguyen-Khac E and Casadei-Gardini A and Borbath I and Tran A and Wege H and Saad AS and Colombo M and Abergel A and Richou C and Waked I and Yee NS and Molﾃｩ A and Attali P and Le Boulicaut J and Vasseur B,Merle,https://pubmed.ncbi.nlm.nih.gov/30954567/,30954567,#VALUE!,0.12244898,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.521126761,0.143089492,1.897924832,0.702970297,0.062779685,7.871451384,0.447662077,1.992008086,0.741321166,-0.299321325,1.397823314,1.243996167,1.068242908,0.857181053,0.640041025
249,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Unclear,Phase 3,NCT02225470,No name,Breast cancer,Breast cancer,Industry,"Eisai Co., Ltd.",2,≥3,≥3,Eribulin mesilate,Chemotherapy,vinorelbine,Chemotherapy,PFS,RECIST 1.1,264,266,NA,0.82,0.67,1,0.8,0.65,0.98,NA,NA,NA,NA,264,81,266,45,13.4,12.5,1.03,0.8,1.31,Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.,"European journal of cancer (Oxford, England : 1990)",10.00,2019,Yuan P and Hu X and Sun T and Li W and Zhang Q and Cui S and Cheng Y and Ouyang Q and Wang X and Chen Z and Hiraiwa M and Saito K and Funasaka S and Xu B,Yuan,https://pubmed.ncbi.nlm.nih.gov/30928806/,30928806,0.084183673,0.084183673,1.025,0.024692613,0.146313506,0.126717765,0.103475321,0.073190792,0.032812985,#VALUE!,#VALUE!,#VALUE!,2.173770492,1.437254641,3.287711179,#VALUE!,0.472055239,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
267,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02684006,JAVELIN Renal101,Renal cell cancer,Renal cell cancer,Industry,Pfizer and Merck,2,1,1,avelumab plus axitinib,Immune checkpoint inhibitor and target therapy,Sunitinib,Target therapy,OS and PFS,RECIST 1.1,442,444,12.0/11.5,0.64,0.525,0.775,0.69,0.56,0.84,442,247,444,134,442,227,444,114,Not reached,Not reached,0.78,0.554,1.084,Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.,The New England journal of medicine,176.08,2019,Motzer RJ and Penkov K and Haanen J and Rini B and Albiges L and Campbell MT and Venugopal B and Kollmannsberger C and Negrier S and Uemura M and Lee JL and Vasiliev A and Miller WH Jr and Gurney H and Schmidinger M and Larkin J and Atkins MB and Bedke J and Alekseev B and Wang J and Mariani M and Robbins PB and Chudnovsky A and Fowst C and Hariharan S and Huang B and di Pietro A and Choueiri TK,Motzer,https://pubmed.ncbi.nlm.nih.gov/30779531/,30779531,0.06377551,0.071428571,0.927536232,-0.075223421,0.143421979,0.124223843,0.101455716,0.071798059,0.03231595,2.930348259,2.223028708,3.86272156,3.05630355,2.302815507,4.056335108,0.418288993,0.447326429,0.958788357,-0.04208492,0.201801792,0.174774145,0.142716644,0.100945923,0.045251633
291,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT02746796,ATTRACTION-4,gastric/gastroesophageal junction cancer,Gastric and gastroesophageal junction cancer,Industry,"Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Inc.",2,1,1,"nivolumab, S-1/capecitabine and oxaliplatin",Immune checkpoint inhibitor and chemotherapy,"nivolumab, capecitabine and oxaliplatin",Immune checkpoint inhibitor and chemotherapy,Safety,RECIST 1.1,21,19,13.2,NA,NA,NA,NA,NA,NA,21,14,17,12,21,12,17,13,11.9,11.2,NA,NA,NA,"Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2019,Boku N and Ryu MH and Kato K and Chung HC and Minashi K and Lee KW and Cho H and Kang WK and Komatsu Y and Tsuda M and Yamaguchi K and Hara H and Fumita S and Azuma M and Chen LT and Kang YK,Boku,https://pubmed.ncbi.nlm.nih.gov/30566590/,30566590,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.833333333,0.209099079,3.321126275,0.41025641,0.099638536,1.689209112,0.793884489,0.405502698,2.03125,0.708651367,1.009448646,0.874247746,0.713884916,0.504929922,0.226301277
333,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Blinding,Phase 3,NCT01945775,EMBRACA,Breast cancer,Breast cancer,Industry,Medivation [Pfizer],2,≥4,≥4,Talazoparib,Target therapy,Standard therapy,Chemotherapy,PFS,RECIST 1.1,287,144,11.2,0.54,0.42,0.69,0.54,0.41,0.71,219,137,114,31,NA,NA,NA,NA,22.3,19.5,0.76,0.55,1.06,Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.,The New England journal of medicine,176.08,2018,Litton JK and Rugo HS and Ettl J and Hurvitz SA and Gonﾃｧalves A and Lee KH and Fehrenbacher L and Yerushalmi R and Mina LA and Martin M and Rochﾃｩ H and Im YH and Quek RGW and Markova D and Tudor IC and Hannah AL and Eiermann W and Blum JL,Litton,https://pubmed.ncbi.nlm.nih.gov/30110579/,30110579,0.068877551,0.076530612,1,0,0.188839097,0.16367739,0.133866992,0.095133879,0.044209974,4.47324941,2.726565585,7.338888304,#VALUE!,#VALUE!,#VALUE!,1.176612939,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
354,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02370498,KEYNOTE-061,Gastric and Gastroesophageal Junction Adenocarcinoma,Gastric and gastroesophageal junction cancer,Industry,"Merck Sharp & Dohme, a subsidiary of Merck & Co.",2,2,2,Pembrolizumab,Immune checkpoint inhibitor,Paclitaxel,Chemotherapy,OS and PFS,RECIST 1.1,296,296,7.9,1.19,1,1.42,1.49,1.25,1.77,296,36,296,45,296,33,296,37,6.7,8.3,0.94,0.79,1.12,"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.","Lancet (London, England)",202.73,2018,Shitara K and ﾃ奔gﾃｼroﾄ殕u M and Bang YJ and Di Bartolomeo M and Mandalﾃ M and Ryu MH and Fornaro L and Olesiﾅгki T and Caglevic C and Chung HC and Muro K and Goekkurt E and Mansoor W and McDermott RS and Shacham-Shmueli E and Chen X and Mayo C and Kang SP and Ohtsu A and Fuchs CS,Shitara,https://pubmed.ncbi.nlm.nih.gov/29880231/,29880231,0.107142857,0.132653061,0.798657718,-0.224822813,0.125998232,0.109118263,0.089095658,0.063002198,0.02818279,0.772307692,0.482048108,1.237343663,0.878326996,0.532903649,1.447650648,0.192677438,0.233353826,0.879294039,-0.128635922,0.350461924,0.303595017,0.248024814,0.17567778,0.079622744
355,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Unclear,Phase 2,NCT01984242,IMmotion150,Renal cell cancer,Renal cell cancer,Industry,"F. Hoffmann-La Roche, AG.",3,1,1,atezolizumab and bevacizumab,Immune checkpoint inhibitor and target therapy,sunitinib,Target therapy,PFS,RECIST 1.1,101,101,20.7,0.82,0.59,1.15,1,0.69,1.45,NA,NA,NA,NA,101,32,101,29,NA,NA,NA,NA,NA,Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.,Nature medicine,87.24,2018,McDermott DF and Huseni MA and Atkins MB and Motzer RJ and Rini BI and Escudier B and Fong L and Joseph RW and Pal SK and Reeves JA and Sznol M and Hainsworth J and Rathmell WK and Stadler WM and Hutson T and Gore ME and Ravaud A and Bracarda S and Suﾃ｡rez C and Danielli R and Gruenwald V and Choueiri TK and Nickles D and Jhunjhunwala S and Piault-Louis E and Thobhani A and Qiu J and Chen DS and Hegde PS and Schiff C and Fine GD and Powles T,McDermott,https://pubmed.ncbi.nlm.nih.gov/29867230/,29867230,0.142857143,0.193877551,0.82,-0.198450939,0.254707716,0.22079198,0.180616102,0.128433851,0.059947614,#VALUE!,#VALUE!,#VALUE!,1.151424288,0.631100287,2.100740433,#VALUE!,0.3749082,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
356,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Unclear,Phase 3,NCT02366143,IMpower150,Non-small cell lung cancer,Non-small cell lung cancer,Industry,F. Hoffmann–La Roche/Genentech,3,1,1,atezolizumab plus bevacizumab plus carboplatin plus paclitaxel,Immune checkpoint inhibitor and target therapy and chemotherapy,bevacizumab plus carboplatin plus paclitaxel,Target therapy and chemotherapy,PFS,RECIST 1.1,400,400,15.4/15.5,0.62,0.52,0.74,0.705,0.588,0.846,353,224,331,159,NA,NA,NA,NA,19.2,14.7,0.78,0.64,0.96,Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.,The New England journal of medicine,176.08,2018,Socinski MA and Jotte RM and Cappuzzo F and Orlandi F and Stroyakovskiy D and Nogami N and Rodrﾃｭguez-Abreu D and Moro-Sibilot D and Thomas CA and Barlesi F and Finley G and Kelsch C and Lee A and Coleman S and Deng Y and Shen Y and Kowanetz M and Lopez-Chavez A and Sandler A and Reck M,Socinski,https://pubmed.ncbi.nlm.nih.gov/29863955/,29863955,0.056122449,0.065816327,0.879432624,-0.128478325,0.129281084,0.111969447,0.09143695,0.064685967,0.029036549,1.878406709,1.383709153,2.549966339,#VALUE!,#VALUE!,#VALUE!,0.297514588,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
371,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator,Blinding,Phase 3,NCT02604342,ALUR,Non-small cell lung cancer,Non-small cell lung cancer,Industry,F. Hoffmann-La Roche Ltd.,2,≥3,≥3,Alectinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,72,35,6.5/5.8,0.15,0.08,0.29,0.32,0.17,0.59,72,27,35,1,NA,NA,NA,NA,12.6,NR,0.89,0.35,2.24,Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2018,Novello S and Maziﾃｨres J and Oh IJ and de Castro J and Migliorino MR and Helland ﾃ and Dziadziuszko R and Griesinger F and Kotb A and Zeaiter A and Cardona A and Balas B and Johannsdottir HK and Das-Gupta A and Wolf J,Novello,https://pubmed.ncbi.nlm.nih.gov/29668860/,29668860,0.053571429,0.107142857,0.46875,-0.757685702,0.456832924,0.395667876,0.323125079,0.22861882,0.10272275,20.4,2.639218037,157.6830691,#VALUE!,#VALUE!,#VALUE!,39.55200281,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
378,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01909453,COLUMBUS,Melanoma,Melanoma,Industry,"Array BioPharma, Novartis.",3,"1, 2",≥1,Encorafenib plus Binimetinib,Target therapy,vemurafenib,Target therapy,PFS,RECIST 1.1,192,191,16.6,0.49,0.37,0.64,0.54,0.41,0.71,192,144,191,94,192,121,191,77,In progress,In progress,In progress,In progress,In progress,"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",The Lancet. Oncology,54.43,2018,Dummer R and Ascierto PA and Gogas HJ and Arance A and Mandala M and Liszkay G and Garbe C and Schadendorf D and Krajsova I and Gutzmer R and Chiarion-Sileni V and Dutriaux C and de Groot JWB and Yamazaki N and Loquai C and Moutouh-de Parseval LA and Pickard MD and Sandor V and Robert C and Flaherty KT,Dummer,https://pubmed.ncbi.nlm.nih.gov/29573941/,29573941,0.068877551,0.076530612,0.907407407,-0.097163748,0.19789494,0.171382107,0.139933006,0.098947792,0.044251566,3.095744681,2.008486811,4.771569859,2.523138833,1.67174296,3.808139003,0.704868124,0.544998991,1.226941871,0.20452479,0.304685521,0.263919829,0.215578491,0.152625343,0.068926213
380,Inclusion,Central,Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT02231749,CheckMate 214 ,Renal cell cancer,Renal cell cancer,Industry,Bristol-Myers Squibb and Ono Pharmaceutical,2,1,1,Nivolumab plus Ipilimumab,Immune checkpoint inhibitor,Sunitinib,Target therapy,"OS, ORR, PFS",RECIST 1.1,550,546,25.2,NA,NA,NA,"0.82 (99.1% CI, 0.64–1.05)",,,425,174,422,119,425,177,422,112,NR,26,"0.63 (99.8% CI, 0.44–0.89)",,,Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.,The New England journal of medicine,176.08,2018,Motzer RJ and Tannir NM and McDermott DF and Arﾃｩn Frontera O and Melichar B and Choueiri TK and Plimack ER and Barthﾃｩlﾃｩmy P and Porta C and George S and Powles T and Donskov F and Neiman V and Kollmannsberger CK and Salman P and Gurney H and Hawkins R and Ravaud A and Grimm MO and Bracarda S and Barrios CH and Tomita Y and Castellano D and Rini BI and Chen AC and Mekan S and McHenry MB and Wind-Rotolo M and Doan J and Sharma P and Hammers HJ and Escudier B,Motzer,https://pubmed.ncbi.nlm.nih.gov/29562145/,29562145,#VALUE!,0,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.765107637,1.324791131,2.351770703,1.975446429,1.478699062,2.639068823,0.261984585,0.296012694,0.893523414,-0.11258274,0.208017391,0.180149637,0.147093673,0.10401541,0.046533118
382,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT01835158,CABOSUN,Renal cell cancer,Renal cell cancer,Public,National Cancer Institute part of the National Institutes of Health,2,1,1,Cabozantinib,Target therapy,Sunitinib,Target therapy,PFS,RECIST 1.1,79,78,35.4,0.56,0.37,0.83,0.48,0.31,0.74,79,26,78,9,79,16,78,7,26.6,21.2,0.8,0.53,1.21,Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.,"European journal of cancer (Oxford, England : 1990)",10.00,2018,Choueiri TK and Hessel C and Halabi S and Sanford B and Michaelson MD and Hahn O and Walsh M and Olencki T and Picus J and Small EJ and Dakhil S and Feldman DR and Mangeshkar M and Scheffold C and George D and Morris MJ,Choueiri,https://pubmed.ncbi.nlm.nih.gov/29550566/,29550566,0.117346939,0.109693878,1.166666667,0.15415068,0.302892679,0.262432532,0.214470726,0.152067588,0.069469694,3.761006289,1.626419084,8.697123911,2.575963719,0.99545293,6.665899391,1.803751231,1.446542464,1.460038533,0.378462828,0.646720955,0.560811256,0.459097525,0.327157163,0.155051045
417,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02151981,AURA3,Non-small cell lung cancer,Non-small cell lung cancer,Industry,AstraZeneca,2,2,2,Osimertinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,279,140,NA,0.3,0.23,0.41,0.28,0.2,0.38,279,181,140,41,279,159,140,41,NA,NA,NA,NA,NA,FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.,The oncologist,5.84,2018,Odogwu L and Mathieu L and Goldberg KB and Blumenthal GM and Larkins E and Fiero MH and Rodriguez L and Bijwaard K and Lee EY and Philip R and Fan I and Donoghue M and Keegan P and McKee A and Pazdur R,Odogwu,https://pubmed.ncbi.nlm.nih.gov/29242281/,29242281,0.045918367,0.045918367,1.071428571,0.068992871,0.220357139,0.19100818,0.156240139,0.111075817,0.051762168,4.459681434,2.874400166,6.919272663,3.199390244,2.072160543,4.939818957,1.031855229,0.731545514,1.393916057,0.332117093,0.315173116,0.272950746,0.222867958,0.157601218,0.070516362
424,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator,Unclear,Phase 3,NCT01290939,EORTC26101,Glioblastoma,Glioblastoma,Industry and Public,F. Hoffmann–La Roche and EORTC Cancer Research Fund,2,2,2,Lomustine plus Bevacizumab,Target therapy and chemotherapy,Lomustine,Chemotherapy,OS,RANO criteria,288,149,13.6/15.3,0.49,0.39,0.61,0.59,0.48,0.74,260,108,137,19,NA,NA,NA,NA,9.1,8.6,0.95,0.74,1.21,Lomustine and Bevacizumab in Progressive Glioblastoma.,The New England journal of medicine,176.08,2017,Wick W and Gorlia T and Bendszus M and Taphoorn M and Sahm F and Harting I and Brandes AA and Taal W and Domont J and Idbaih A and Campone M and Clement PM and Stupp R and Fabbro M and Le Rhun E and Dubois F and Weller M and von Deimling A and Golfinopoulos V and Bromberg JC and Platten M and Klein M and van den Bent MJ,Wick,https://pubmed.ncbi.nlm.nih.gov/29141164/,29141164,0.056122449,0.066326531,0.830508475,-0.185717146,0.158791448,0.137529776,0.112312752,0.079459861,0.035688117,4.412742382,2.56206854,7.600224206,#VALUE!,#VALUE!,#VALUE!,1.285243793,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
447,Inclusion,Investigator + Central,Investigator + Central,No ORR,No ORR,Unclear,Phase 3,NCT01719536,CONVINCE,Non-small cell lung cancer,Non-small cell lung cancer,Industry and Public,"Betta Pharmaceuticals Co., Ltd. and National Key Special Program for Innovative Drugs",2,1,1,icotinib,Target therapy,cisplatin/pemetrexed plus pemetrexed maintenance therapy,Chemotherapy,PFS,RECIST 1.1,148,148,18.0/15.7,0.65,0.48,0.88,0.61,0.43,0.87,NA,NA,NA,NA,NA,NA,NA,NA,30.5,32.1,NA,NA,NA,"First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2017,Shi YK and Wang L and Han BH and Li W and Yu P and Liu YP and Ding CM and Song X and Ma ZY and Ren XL and Feng JF and Zhang HL and Chen GY and Han XH and Wu N and Yao C and Song Y and Zhang SC and Song W and Liu XQ and Zhao SJ and Lin YC and Ye XQ and Li K and Shu YQ and Ding LM and Tan FL and Sun Y,Shi,https://pubmed.ncbi.nlm.nih.gov/28945850/,28945850,0.102040816,0.112244898,1.06557377,0.063513406,0.237123348,0.205739378,0.168611687,0.120545055,0.058412994,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
475,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT01605396,No name,Breast cancer,Breast cancer,Industry,"Merck & Co., Inc.",2,≥2,≥2,"ridaforolimus, dalotuzumab and exemestane",Target therapy and chemotherapy,ridaforolimus and exemestane,Target therapy and chemotherapy,PFS,RECIST 1.1,40,40,NA,1.58,1.13,2.19,1.18,0.81,1.72,40,5,40,9,40,6,40,10,NA,NA,NA,NA,NA,"A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.",Breast cancer research and treatment,4.62,2017,Rugo HS and Trﾃｩdan O and Ro J and Morales SM and Campone M and Musolino A and Afonso N and Ferreira M and Park KH and Cortes J and Tan AR and Blum JL and Eaton L and Gause CK and Wang Z and Im E and Mauro DJ and Jones MB and Denker A and Baselga J,Rugo,https://pubmed.ncbi.nlm.nih.gov/28681171/,28681171,0.270408163,0.232142857,1.338983051,0.291910409,0.25572664,0.221772144,0.181575476,0.129446602,0.061529166,0.492063492,0.148898351,1.626119289,0.529411765,0.171886812,1.630589422,0.376842076,0.372118013,0.929453263,-0.073158755,0.837467832,0.725490822,0.592723795,0.419888154,0.190509091
492,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01828112,ASCEND-5,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Novartis Pharmaceuticals Corporation.,2,≥2,≥2,Ceritinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,115,116,16.5,0.4,0.29,0.54,0.49,0.36,0.67,115,49,116,7,115,45,116,8,18.1,20.1,1,0.67,1.49,"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.",The Lancet. Oncology,54.43,2017,Shaw AT and Kim TM and Crinﾃｲ L and Gridelli C and Kiura K and Liu G and Novello S and Bearz A and Gautschi O and Mok T and Nishio M and Scagliotti G and Spigel DR and Deudon S and Zheng C and Pantano S and Urban P and Massacesi C and Viraswami-Appanna K and Felip E,Shaw,https://pubmed.ncbi.nlm.nih.gov/28602779/,28602779,0.06377551,0.079081633,0.816326531,-0.202940844,0.224192896,0.194156754,0.158528344,0.112096505,0.050131219,11.56060606,4.946558908,27.01829999,8.678571429,3.860924933,19.50765771,5.630546194,3.991513464,1.332086295,0.286746356,0.598630378,0.518524378,0.423528904,0.299809831,0.135252713
493,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Unclear,Phase 3,NCT02075840,ALEX,Non-small cell lung cancer,Non-small cell lung cancer,Industry,F. Hoffmann-La Roche Ltd.,2,1,1,Alectinib,Target therapy,Crizotinib,Target therapy,PFS,RECIST 1.1,152,151,17.6/18.6,0.47,0.34,0.65,0.5,0.36,0.7,152,126,151,114,NA,NA,NA,NA,NA,NA,0.76,0.48,1.2,Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.,The New England journal of medicine,176.08,2017,Peters S and Camidge DR and Shaw AT and Gadgeel S and Ahn JS and Kim DW and Ou SI and Pﾃｩrol M and Dziadziuszko R and Rosell R and Zeaiter A and Mitry E and Golding S and Balas B and Noe J and Morcos PN and Mok T,Peters,https://pubmed.ncbi.nlm.nih.gov/28586279/,28586279,0.079081633,0.086734694,0.94,-0.061875404,0.236864978,0.205142481,0.167516736,0.118491672,0.053132024,1.572874494,0.896705709,2.758914266,#VALUE!,#VALUE!,#VALUE!,0.475053203,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
494,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT02000622,OlympiAD,Breast cancer,Breast cancer,Industry,AstraZeneca,2,"1, 2",≥1,Olaparib,Target therapy,Standard care,Standard care,PFS,RECIST 1.1,205,97,14.5/14.1,0.5,0.36,0.68,0.58,0.43,0.8,NA,NA,NA,NA,167,100,66,19,19.3,19.6,0.9,0.63,1.29,Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.,The New England journal of medicine,176.08,2017,Robson M and Im SA and Senkus E and Xu B and Domchek SM and Masuda N and Delaloge S and Li W and Tung N and Armstrong A and Wu W and Goessl C and Runswick S and Conte P,Robson,https://pubmed.ncbi.nlm.nih.gov/28578601/,28578601,0.081632653,0.094387755,0.862068966,-0.148420005,0.226726347,0.1963603,0.160343065,0.113412652,0.050837531,#VALUE!,#VALUE!,#VALUE!,3.692065986,1.993725988,6.83712372,#VALUE!,1.235560646,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
501,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,JapicCTI-132316,J-ALEX,Non-small cell lung cancer,Non-small cell lung cancer,Industry,"Chugai Pharmaceutical Co, Ltd.",2,1,1,Alectinib,Target therapy,Crizotinib,Target therapy,PFS,RECIST 1.1,103,104,12.0/12.2,0.34,0.21,0.54,0·34 [99·7% CI 0·17–0·71],,,103,88,104,73,83,76,90,71,In progress,In progress,In progress,In progress,In progress,"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.","Lancet (London, England)",202.73,2017,Hida T and Nokihara H and Kondo M and Kim YH and Azuma K and Seto T and Takiguchi Y and Nishio M and Yoshioka H and Imamura F and Hotta K and Watanabe S and Goto K and Satouchi M and Kozuki T and Shukuya T and Nakagawa K and Mitsudomi T and Yamamoto N and Asakawa T and Asabe R and Tanaka T and Tamura T,Hida,https://pubmed.ncbi.nlm.nih.gov/28501140/,28501140,0.084183673,0.090909091,0,0,0.340532089,0.294909474,0.240792633,0.170266221,0.07614579,2.491324201,1.249399883,4.967742001,2.905432596,1.15208355,7.327193039,0.948556663,1.575283033,0.857471003,-0.153767917,0.588827752,0.513447334,0.42489788,0.312167027,0.176000817
504,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Unclear,Phase 3,NCT01026142,PHEREXA,Breast cancer,Breast cancer,Industry,AstraZeneca,2,≥2,≥2,"Pertuzumab, Trastuzumab Plus Capecitabine",Target therapy and chemotherapy,Trastuzumab Plus Capecitabine,Target therapy and chemotherapy,PFS,RECIST 1.1,228,224,28.6/25.3,0.81,0.66,1,0.82,0.65,1.02,NA,NA,NA,NA,163,66,164,54,28.1,36.1,0.68,0.51,0.9,Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2017,Urruticoechea A and Rizwanullah M and Im SA and Ruiz ACS and Lﾃ｡ng I and Tomasello G and Douthwaite H and Badovinac Crnjevic T and Heeson S and Eng-Wong J and Muﾃｱoz M,Urruticoechea,https://pubmed.ncbi.nlm.nih.gov/28437161/,28437161,0.086734694,0.094387755,0.987804878,-0.012270093,0.156359118,0.135484833,0.110743426,0.07856254,0.036033953,#VALUE!,#VALUE!,#VALUE!,1.3860252,0.882422225,2.177037027,#VALUE!,0.330258878,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
511,Inclusion,Investigator + Central,Investigator + Central,Unclear,Central,Blinding,Phase 3,NCT00569127,SWOG S0518,Neuroendocrine tumors,Neuroendocrine tumors,Industry,"Novartis, Pharmacyclics",2,2,2,bevacizumab plus octreotide,Target therapy and chemotherapy,interferon plus octreotide,Immunotherapy and chemotherapy,PFS,RECIST 1.1,214,213,NA,0.9,0.72,1.12,0.93,0.73,1.18,NA,NA,NA,NA,214,24,213,8,35.2,Not reached,1.16,0.88,1.55,Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2017,Yao JC and Guthrie KA and Moran C and Strosberg JR and Kulke MH and Chan JA and LoConte N and McWilliams RR and Wolin EM and Mattar B and McDonough S and Chen H and Blanke CD and Hochster HS,Yao,https://pubmed.ncbi.nlm.nih.gov/28384065/,28384065,0.102040816,0.114795918,0.967741935,-0.032789823,0.166468968,0.144249501,0.117914884,0.083665531,0.03842814,#VALUE!,#VALUE!,#VALUE!,3.236842105,1.419702071,7.379820757,#VALUE!,1.52043844,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
523,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT01234857,No name,Breast cancer,Breast cancer,Industry,"Merck & Co., Inc.",4,≥2,≥2,ridaforolimus 30 mg plus dalotuzumab,Target therapy,Exemestane,Chemotherapy,PFS,RECIST 1.1,29,33,NA,0.99,0.53,1.87,1,0.46,2.19,29,2,33,1,29,1,33,0,24.7,24.9,1.28,0.65,2.49,A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.,Breast cancer research and treatment,4.62,2017,Baselga J and Morales SM and Awada A and Blum JL and Tan AR and Ewertz M and Cortes J and Moy B and Ruddy KJ and Haddad T and Ciruelos EM and Vuylsteke P and Ebbinghaus S and Im E and Eaton L and Pathiraja K and Gause C and Mauro D and Jones MB and Rugo HS,Baselga,https://pubmed.ncbi.nlm.nih.gov/28324268/,28324268,0.341836735,0.441326531,0.99,-0.010050336,0.511770655,0.444850949,0.365890053,0.264307954,0.13654752,2.37037037,0.203622676,27.59346753,2.321428571,0.075016493,71.83794397,6.987205321,18.30686925,1.021082621,0.020863458,2.152851726,1.881032838,1.562625521,1.159876071,0.684195649
524,Inclusion,No PFS,No PFS,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT00874848,No name,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Biothera Pharmaceuticals Inc.,2,1,1,BTH1677,Immunotherapy,cetuximab/carboplatin/paclitaxel,Target therapy/Chemotherapy,ORR,RECIST 1.0,60,30,NA,NA,NA,NA,NA,NA,NA,46,22,26,6,41,15,26,6,10.3,12.4,1.14,0.67,2,"A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.",Investigational new drugs,3.65,2017,Thomas M and Sadjadian P and Kollmeier J and Lowe J and Mattson P and Trout JR and Gargano M and Patchen ML and Walsh R and Beliveau M and Marier JF and Bose N and Gorden K and Schneller F 3rd,Thomas,https://pubmed.ncbi.nlm.nih.gov/28303530/,28303530,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,3.055555556,1.037349704,9.000262611,1.923076923,0.63259677,5.846101384,2.031355333,1.329975667,1.588888889,0.46303496,0.790937893,0.68501961,0.559393405,0.395714667,0.177553908
526,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT01763164,NEMO,Melanoma,Melanoma,Industry,Array BioPharma and Novartis Pharmaceuticals Corporation.,2,≥2,≥2,Binimetinib,Target therapy,Dacarbazine,Chemotherapy,PFS,RECIST 1.1,269,133,1.7,0.63,0.48,0.82,0.62,0.47,0.8,NA,NA,NA,NA,269,41,133,9,11,10.1,1,0.75,1.33,"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.",The Lancet. Oncology,54.43,2017,Dummer R and Schadendorf D and Ascierto PA and Arance A and Dutriaux C and Di Giacomo AM and Rutkowski P and Del Vecchio M and Gutzmer R and Mandala M and Thomas L and Demidov L and Garbe C and Hogg D and Liszkay G and Queirolo P and Wasserman E and Ford J and Weill M and Sirulnik LA and Jehl V and Bozﾃｳn V and Long GV and Flaherty K,Dummer,https://pubmed.ncbi.nlm.nih.gov/28284557/,28284557,0.086734694,0.084183673,1.016129032,0.016000341,0.192542917,0.166747703,0.136149985,0.096274816,0.043063413,#VALUE!,#VALUE!,#VALUE!,2.477582846,1.165766806,5.265561455,#VALUE!,1.045865982,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
529,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,JapicCTI-090921,No name,Breast cancer,Breast cancer,Industry,"Taiho Pharmaceutical Co.,Ltd.",2,1,1,nab-paclitaxel,Chemotherapy,docetaxel,Chemotherapy,PFS,RECIST 1.1,100,100,23,0.81 (90%CI 0.59 to 1.10),,,1.25 (90%CI 0.91 to 1.72),,,98,60,99,54,98,55,99,52,42.4,34,0.78,0.54,1.14,Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.,Cancer science,6.52,2017,Tamura K and Inoue K and Masuda N and Takao S and Kashiwaba M and Tokuda Y and Iwata H and Yamamoto N and Aogi K and Saeki T and Nakayama T and Sato N and Toyama T and Ishida T and Arioka H and Saito M and Ohno S and Yamauchi H and Yamada K and Watanabe J and Ishiguro H and Fujiwara Y,Tamura,https://pubmed.ncbi.nlm.nih.gov/28256066/,28256066,0.154545455,0.245454545,0.648,-0.433864583,0.269911724,0.233759616,0.190878959,0.135003689,0.060489431,1.315789474,0.746254645,2.319988158,1.15608229,0.659658261,2.026088871,0.401462631,0.348579237,1.13814517,0.129399893,0.407023579,0.352496144,0.287817423,0.203529374,0.091063033
536,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT02253459,No name,Breast cancer,Breast cancer,Industry,Beijing Biostar Technologies,2,≥2,≥2,Utidelone plus capecitabine,Chemotherapy,capecitabine,Chemotherapy,PFS,RECIST 1.1,270,135,6.77/4.55,0.67,0.53,0.84,0.46,0.36,0.59,270,107,135,38,270,109,135,29,16.13,12.78,0.63,0.45,0.88,"Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.",The Lancet. Oncology,54.43,2017,Zhang P and Sun T and Zhang Q and Yuan Z and Jiang Z and Wang XJ and Cui S and Teng Y and Hu XC and Yang J and Pan H and Tong Z and Li H and Yao Q and Wang Y and Yin Y and Sun P and Zheng H and Cheng J and Lu J and Zhang B and Geng C and Liu J and Peng R and Yan M and Zhang S and Huang J and Tang L and Qiu R and Xu B,Zhang,https://pubmed.ncbi.nlm.nih.gov/28209298/,28209298,0.079081633,0.058673469,1.456521739,0.376051223,0.172290686,0.149269259,0.121977632,0.086462557,0.039415209,1.675653859,1.071222047,2.621133369,2.474619833,1.535393478,3.988386954,0.395385541,0.625763642,0.677135872,-0.389883329,0.333778436,0.289161201,0.236263319,0.167411205,0.076101487
544,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01828099,ASCEND-4,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Novartis Pharmaceuticals Corporation.,2,1,1,Ceritinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,189,187,19.7?,0.49,0.37,0.64,0.55,0.42,0.73,189,139,187,60,189,137,187,50,NR,26.2,0.73,0.5,1.08,"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","Lancet (London, England)",202.73,2017,Soria JC and Tan DSW and Chiari R and Wu YL and Paz-Ares L and Wolf J and Geater SL and Orlov S and Cortinovis D and Yu CJ and Hochmair M and Cortot AB and Tsai CM and Moro-Sibilot D and Campelo RG and McCulloch T and Sen P and Dugan M and Pantano S and Branle F and Massacesi C and de Castro G Jr,Soria,https://pubmed.ncbi.nlm.nih.gov/28126333/,28126333,0.068877551,0.079081633,0.890909091,-0.115512887,0.198560918,0.1719599,0.140406469,0.09928618,0.044415774,5.884333333,3.767777535,9.189868154,7.218846154,4.581162105,11.37522284,1.383186383,1.733178758,0.815134886,-0.204401676,0.324906504,0.281386517,0.229766201,0.162501208,0.072787026
567,Inclusion,Investigator + Central,No PFS,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT01528163,No name,"Squamous Cell Carcinoma
of the Head andNeck",Head and Neck Cancer,Public,Cliniques Universitaires Saint-Luc,2,2,2,Cabazitaxel,Target therapy,Methotrexate,chemotherapy,PFS,RECIST 1.1,53,48,3.6,NA,NA,NA,NA,NA,NA,53,0,48,1,53,0,48,0,5,3.6,NA,NA,NA,Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.,The oncologist,5.84,2016,Machiels JP and Van Maanen A and Vandenbulcke JM and Filleul B and Seront E and Henry S and D'Hondt L and Lonchay C and Holbrechts S and Boegner P and Brohee D and Dequanter D and Louviaux I and Sautois B and Whenham N and Berchem G and Vanderschueren B and Fontaine C and Schmitz S and Gillain A and Schoonjans J and Rottey S,Machiels,https://pubmed.ncbi.nlm.nih.gov/27903924/,27903924,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.447619048,0.014678496,13.65009183,0.914285714,0.017788337,46.9924976,3.47842177,11.9833442,0.489583333,-0.71420059,2.6609067,2.308257698,1.890947575,1.350300657,0.64916498
612,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator + Central,Blinding,Phase 2,NCT01185964,No name,soft-tissue sarcoma,Sarcoma,Industry,Eli Lilly and Company.,2,≥1,≥1,Olaratumab and doxorubicin,Target therapy and chemotherapy,doxorubicin,chemotherapy,PFS,RECIST 1.1,66,67,NA,0.672,0.442,1.021,0.67,0.4,1.12,66,12,67,8,66,12,67,5,26.5,14.7,0.46,0.3,0.71,Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.,"Lancet (London, England)",202.73,2016,Tap WD and Jones RL and Van Tine BA and Chmielowski B and Elias AD and Adkins D and Agulnik M and Cooney MM and Livingston MB and Pennock G and Hameed MR and Shah GD and Qin A and Shahir A and Cronier DM and Ilaria R Jr and Conti I and Cosaert J and Schwartz GK,Tap,https://pubmed.ncbi.nlm.nih.gov/27291997/,27291997,0.147704082,0.183673469,1.002985075,0.002980628,0.338533649,0.294203964,0.241882022,0.174521784,0.089546665,1.638888889,0.622659663,4.313683621,2.755555556,0.912451011,8.321637361,0.941587744,1.890098559,0.594758065,-0.51960057,0.749521106,0.650050902,0.532306737,0.379650826,0.181003258
614,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01865747,METEOR,Renal cell cancer,Renal cell cancer,Industry,Exelixis Inc.,2,≥2,≥2,Cabozantinib,Target therapy,everolimus,Target therapy,PFS,RECIST 1.1,330,328,18.7/18.8,0.54,0.44,0.65,0.52,0.42,0.64,330,78,328,14,330,57,328,11,21.4,16.5,0.66,0.53,0.83,"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.",The Lancet. Oncology,54.43,2016,Choueiri TK and Escudier B and Powles T and Tannir NM and Mainwaring PN and Rini BI and Hammers HJ and Donskov F and Roth BJ and Peltola K and Lee JL and Heng DYC and Schmidinger M and Agarwal N and Sternberg CN and McDermott DF and Aftab DT and Hessel C and Scheffold C and Schwab G and Hutson TE and Pal S and Motzer RJ,Choueiri,https://pubmed.ncbi.nlm.nih.gov/27279544/,27279544,0.053571429,0.056122449,1.038461538,0.037740328,0.146472781,0.126910824,0.103722896,0.073556244,0.03364798,6.942176871,3.8383902,12.55573748,6.016983017,3.092983951,11.70522874,2.223813082,2.197001221,1.153763747,0.143029422,0.45461256,0.394144848,0.322533319,0.229576399,0.107923064
631,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Unclear,Phase 2,NCT01323400,PAZOGIST,gastrointestinal stromal tumours,Gastrointestinal stromal tumours,Industry and Public,"GlaxoSmithKline, French National Cancer Institute, EuroSARC (FP7-278742), Centre Léon Bérard.",2,≥2,≥2,Pazopanib plus best supportive care,Target therapy plus best supportive care,best supportive care,best supportive care,PFS,RECIST 1.1,40,41,26.4/28.9,0.59,0.37,0.96,0.7,0.44,1.11,NA,NA,NA,NA,40,32,41,29,17.8,12.9,0.94,0.56,1.56,"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.",The Lancet. Oncology,54.43,2016,Mir O and Cropet C and Toulmonde M and Cesne AL and Molimard M and Bompas E and Cassier P and Ray-Coquard I and Rios M and Adenis A and Italiano A and Bouchﾃｩ O and Chauzit E and Duffaud F and Bertucci F and Isambert N and Gautier J and Blay JY and Pﾃｩrol D,Mir,https://pubmed.ncbi.nlm.nih.gov/27068858/,27068858,0.150510204,0.170918367,0.842857143,-0.170957798,0.338938796,0.293551473,0.239719477,0.169582982,0.076110156,#VALUE!,#VALUE!,#VALUE!,1.655172414,0.593225471,4.618135688,#VALUE!,1.02676281,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
672,Inclusion,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 2,JapicCTI-111554,No name,Pancretic cancer,Pancretic cancer,Industry,"Taiho Pharmaceutical Co., Ltd",2,2,2,leucovorin plus S-1 ,Chemotherapy,S-1,Chemotherapy,PFS,RECIST 1.1,71,71,NA,0.73,0.51,1.06,0.56,0.37,0.85,69,16,71,12,69,19,71,14,6.3,6.1,0.82,0.54,1.22,A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2016,Ueno M and Okusaka T and Omuro Y and Isayama H and Fukutomi A and Ikeda M and Mizuno N and Fukuzawa K and Furukawa M and Iguchi H and Sugimori K and Furuse J and Shimada K and Ioka T and Nakamori S and Baba H and Komatsu Y and Takeuchi M and Hyodo I and Boku N,Ueno,https://pubmed.ncbi.nlm.nih.gov/26681680/,26681680,0.140306122,0.12244898,1.303571429,0.26510775,0.282581058,0.245055349,0.200629492,0.143011407,0.067914048,1.48427673,0.643757275,3.422217498,1.547142857,0.703624735,3.401885839,0.708790873,0.688331914,0.959366307,-0.041482309,0.585879186,0.507530572,0.414632539,0.293688617,0.133113833
679,Inclusion,Investigator + Central,Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,JapicCTI-111635,No name,Gastric cancer,Gastric and gastroesophageal junction cancer,Industry,"Taiho Pharmaceutical Co., Ltd",3,1,1,S-1 plus leucovorin and oxaliplatin,Chemotherapy,S-1 plus cisplatin,Chemotherapy,ORR,RECIST 1.1,47,49,25.9,NA,NA,NA,0.6,0.35,1.02,47,28,48,20,47,31,48,22,18.4,12.6,0.59,0.37,0.93,"S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.",The Lancet. Oncology,54.43,2016,Hironaka S and Sugimoto N and Yamaguchi K and Moriwaki T and Komatsu Y and Nishina T and Tsuji A and Nakajima TE and Gotoh M and Machida N and Bando H and Esaki T and Emi Y and Sekikawa T and Matsumoto S and Takeuchi M and Boku N and Baba H and Hyodo I,Hironaka,https://pubmed.ncbi.nlm.nih.gov/26640036/,26640036,#VALUE!,0.170918367,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,2.063157895,0.910752264,4.673741332,2.289772727,0.999963214,5.24325202,0.959946191,1.082471634,0.901031736,-0.104214799,0.593914387,0.514352281,0.419978855,0.2969953,0.13291119
706,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT00864253,No name,Melanoma,Melanoma,Industry,Celgene Corporation,2,1,1,nab-Paclitaxel,Chemotherapy,Dacarbazine,Chemotherapy,PFS,RECIST 1.0,264,265,NA,0.845,0.696,1.025,0.792,0.631,0.992,NA,NA,NA,NA,264,39,265,30,12.6,10.5,0.897,0.738,1.089,"A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naﾃｯve patients with metastatic melanoma.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2015,Hersh EM and Del Vecchio M and Brown MP and Kefford R and Loquai C and Testori A and Bhatia S and Gutzmer R and Conry R and Haydon A and Robert C and Ernst S and Homsi J and Grob JJ and Kendra K and Agarwala SS and Li M and Clawson A and Brachmann C and Karnoub M and Elias I and Renschler MF and Hauschild A,Hersh,https://pubmed.ncbi.nlm.nih.gov/26410620/,26410620,0.083928571,0.092091837,1.066919192,0.064775236,0.151893163,0.131806918,0.108049037,0.077305403,0.037647707,#VALUE!,#VALUE!,#VALUE!,1.357777778,0.815437963,2.2608225,#VALUE!,0.368720545,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
710,Inclusion,Investigator + Central,No PFS,Investigator + Central,Investigator + Central,Blinding,Phase 2B,NCT01514188,No name,Soft-Tissue Sarcoma,Sarcoma,Industry,CytRx Corporation,2,1,1,aldoxorubicin,Chemotherapy,doxorubicin,Chemotherapy,PFS,RECIST 1.1,86,40,13,No HR,No HR,No HR,No HR,No HR,No HR,83,19,40,2,80,20,38,0,15.8,14.3,0.73,0.44,1.2,First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.,JAMA oncology,33.01,2015,Chawla SP and Papai Z and Mukhametshina G and Sankhala K and Vasylyev L and Fedenko A and Khamly K and Ganjoo K and Nagarkar R and Wieland S and Levitt DJ,Chawla,https://pubmed.ncbi.nlm.nih.gov/26378637/,26378637,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,5.640625,1.244417943,25.56749569,25.33333333,1.48634966,431.7811582,6.204866772,109.7690838,0.22265625,-1.502126177,1.639483364,1.459482422,1.253902779,1.007201776,0.753791754
711,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Blinding,Phase 3,NCT01343277,ET743-SAR-3007,Liposarcoma or Leiomyosarcoma,Liposarcoma or Leiomyosarcoma,Industry,"Janssen Pharmaceuticals, Novartis, Pfizer, Bayer, Threshold Pharmaceuticals, EMD Serono",2,≥2,≥2,Trabectedin,Chemotherapy,Dacarbazine,Chemotherapy,OS,RECIST 1.1,345,173,8.6,0.58,0.43,0.79,0.55,0.4,0.75,345,34,173,12,NA,NA,NA,NA,12.4,12.9,0.87,NA,P=0.37,Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2016,Demetri GD and von Mehren M and Jones RL and Hensley ML and Schuetze SM and Staddon A and Milhem M and Elias A and Ganjoo K and Tawbi H and Van Tine BA and Spira A and Dean A and Khokhar NZ and Park YC and Knoblauch RE and Parekh TV and Maki RG and Patel SR,Demetri,https://pubmed.ncbi.nlm.nih.gov/26371143/,26371143,0.091836735,0.089285714,1.054545455,0.053109825,0.223139806,0.193262191,0.157826411,0.111660545,0.050151755,1.466773848,0.739327086,2.909977954,#VALUE!,#VALUE!,#VALUE!,0.553737466,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
733,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01523587,LUX-Lung 8,Squamous cell carcinoma of the lung,Squamous cell carcinoma of the lung,Industry,Boehringer Ingelheim,2,2,2,Afatinib,Target therapy,Erlotinib,Target therapy,PFS,RECIST 1.1,398,397,18.4,0.79,0.68,0.91,0.81,0.69,0.96,398,43,397,16,398,22,397,11,7.9,6.8,0.81,0.69,0.95,Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.,The Lancet. Oncology,54.43,2015,Soria JC and Felip E and Cobo M and Lu S and Syrigos K and Lee KH and Gﾃｶker E and Georgoulias V and Li W and Isla D and Guclu SZ and Morabito A and Min YJ and Ardizzoni A and Gadgeel SM and Wang B and Chand VK and Goss GD,Soria,https://pubmed.ncbi.nlm.nih.gov/26156651/,26156651,0.058673469,0.068877551,0.975308642,-0.025001302,0.112344994,0.097419989,0.079749049,0.056825764,0.026917888,2.884330986,1.595830736,5.213187747,2.053191489,0.981979987,4.292954386,0.922795156,0.844636326,1.404803693,0.339897572,0.482505204,0.419511126,0.345207037,0.249692234,0.129957157
739,Inclusion,Investigator,Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT01401192,No name,Non-small cell lung cancer,Non-small cell lung cancer,Public,Korea Healthcare Technology R&D Project,4?,1,1,Pemetrexed Plus Cisplatin,Chemotherapy,Gemcitabine Plus Cisplatin,Chemotherapy,ORR,RECIST 1.1,162,159,19.1,NA,NA,NA,0.65,0.46,0.91,162,71,159,48,162,63,159,56,27.3,23.7,0.88,0.64,1.23,Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2015,Sun JM and Ahn JS and Jung SH and Sun J and Ha SY and Han J and Park K and Ahn MJ,Sun,https://pubmed.ncbi.nlm.nih.gov/26124486/,26124486,#VALUE!,0.114795918,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.804258242,1.139786026,2.856104329,1.170454545,0.743693576,1.842107942,0.437836302,0.280207747,1.541502187,0.432757387,0.329326232,0.285208709,0.232878182,0.164682993,0.073695865
741,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 2,NCT01704287,KEYNOTE-002,Melanoma,Melanoma,Industry,Merck Sharp & Dohme,3,≥2,≥2,Pembrolizumab 10mg,Immune checkpoint inhibitor,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,181,179,10,0.41,0.32,0.52,0.5,0.39,0.64,NA,NA,NA,NA,181,46,179,8,NA,NA,NA,NA,NA,"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.",The Lancet. Oncology,54.43,2015,Ribas A and Puzanov I and Dummer R and Schadendorf D and Hamid O and Robert C and Hodi FS and Schachter J and Pavlick AC and Lewis KD and Cranmer LD and Blank CU and O'Day SJ and Ascierto PA and Salama AK and Margolin KA and Loquai C and Eigentler TK and Gangadhar TC and Carlino MS and Agarwala SS and Moschos SJ and Sosman JA and Goldinger SM and Shapira-Frommer R and Gonzalez R and Kirkwood JM and Wolchok JD and Eggermont A and Li XN and Zhou W and Zernhelt AM and Lis J and Ebbinghaus S and Kang SP and Daud A,Ribas,https://pubmed.ncbi.nlm.nih.gov/26115796/,26115796,0.051020408,0.06377551,0.82,-0.198450939,0.176935135,0.153235435,0.125124557,0.08849413,0.039639073,#VALUE!,#VALUE!,#VALUE!,7.283333333,3.325440445,15.9518552,#VALUE!,3.221024172,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
745,Inclusion,Investigator + Central,Investigator + Central,Unclear,Central,Blinding,Phase 3,NCT01342965,ENSURE,Non-small cell lung cancer,Non-small cell lung cancer,Industry,F. Hoffmann-La Roche,2,1,1,erlotinib,Target therapy,gemcitabine/cisplatin,Chemotherapy,PFS,RECIST 1.1,110,107,28.9/27.1,0.34,0.22,0.51,0.42,0.27,0.66,NA,NA,NA,NA,110,69,107,36,26.3,25.5,0.91,0.63,1.31,"First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2015,Wu YL and Zhou C and Liam CK and Wu G and Liu X and Zhong Z and Lu S and Cheng Y and Han B and Chen L and Huang C and Qin S and Zhu Y and Pan H and Liang H and Li E and Jiang G and How SH and Fernando MCL and Zhang Y and Xia F and Zuo Y,Wu,https://pubmed.ncbi.nlm.nih.gov/26105600/,26105600,0.073979592,0.099489796,0.80952381,-0.211309094,0.313041155,0.271185976,0.221560156,0.156958503,0.071229397,#VALUE!,#VALUE!,#VALUE!,3.319105691,1.901698387,5.792959948,#VALUE!,0.992668766,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
754,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT00739830,No name,Endometrial Carcinoma,Endometrial Carcinoma,Industry,"AstraZeneca, Roche, Immunovaccine, Immunogen",2,≥2,≥2,Ridaforolimus,Target therapy,progestin or chemotherapy,Chemotherapy,PFS,RECIST 1.0,64,66,NA,0.39,0.23,0.66,0.53,0.31,0.9,48,4,47,2,48,0,47,2,10,9.6,1.06,0.7,1.59,Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2015,Oza AM and Pignata S and Poveda A and McCormack M and Clamp A and Schwartz B and Cheng J and Li X and Campbell K and Dodion P and Haluska FG,Oza,https://pubmed.ncbi.nlm.nih.gov/26077241/,26077241,0.109693878,0.150510204,0.735849057,-0.306730267,0.38241761,0.331186705,0.270418268,0.191226162,0.085560326,2.045454545,0.35632402,11.74179696,0.236842105,0.010398428,5.394486852,2.904457383,1.373491945,8.636363636,2.155981619,1.827080827,1.620888233,1.384316792,1.097901315,0.79789144
776,Inclusion,Investigator + Central,Investigator + Central,Unclear,No ORR,Unclear,Phase 2,NCT00842712,CERTO,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Merck KGaA,3,1,1,cetuximab plus platinum-based chemotherapy plus cilengitide 2000 mg 1×/week,Target therapy and chemotherapy,cetuximab plus platinum-based chemotherapy,Target therapy and Chemotherapy,PFS,RECIST 1.0 or 1.1,85,84,NA,0.909,0.642,1.286,0.718,0.492,1.048,NA,NA,NA,NA,NA,NA,NA,NA,13.6,9.7,0.813,0.564,1.171,"Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2015,Vansteenkiste J and Barlesi F and Waller CF and Bennouna J and Gridelli C and Goekkurt E and Verhoeven D and Szczesna A and Feurer M and Milanowski J and Germonpre P and Lena H and Atanackovic D and Krzakowski M and Hicking C and Straub J and Picard M and Schuette W and O'Byrne K,Vansteenkiste,https://pubmed.ncbi.nlm.nih.gov/25939894/,25939894,0.164285714,0.141836735,1.266016713,0.235875525,0.261947846,0.226988883,0.185556547,0.13167578,0.060533744,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
786,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01345682,LUX-Head & Neck 1,Head and Neck Cancer,Head and Neck Cancer,Industry,Boehringer Ingelheim,2,2,2,Afatinib,Target therapy,methotrexate,Chemotherapy,PFS,RECIST 1.1,322,161,6.7,0.79,0.64,0.98,0.8,0.65,0.98,322,38,161,7,322,33,161,9,6.8,6,0.96,0.77,1.19,"Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.",The Lancet. Oncology,54.43,2015,Machiels JP and Haddad RI and Fayette J and Licitra LF and Tahara M and Vermorken JB and Clement PM and Gauler T and Cupissol D and Grau JJ and Guigay J and Caponigro F and de Castro G Jr and de Souza Viana L and Keilholz U and Del Campo JM and Cong XJ and Ehrnrooth E and Cohen EE,Machiels,https://pubmed.ncbi.nlm.nih.gov/25892145/,25892145,0.086734694,0.084183673,0.9875,-0.012578782,0.150947139,0.130739014,0.106772379,0.075551255,0.033972238,2.943661972,1.283994023,6.748587337,1.928489043,0.899391908,4.135093896,1.394028906,0.825434181,1.526408451,0.422917558,0.575013793,0.498268958,0.407311978,0.289022733,0.132811952
788,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00785785,ENESTg1,Gastrointestinal stromal tumours,Gastrointestinal stromal tumours,Industry,Novartis Pharmaceuticals,2,1,1,Nilotinib,Target therapy,Imatinib,Target therapy,PFS,RECIST 1.0,324,320,28,1.62,1.24,2.12,1.25,0.92,1.7,324,132,320,150,324,139,320,165,81.8,90,1.85,1.2,2.86,Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.,The Lancet. Oncology,54.43,2015,Blay JY and Shen L and Kang YK and Rutkowski P and Qin S and Nosov D and Wan D and Trent J and Srimuninnimit V and Pﾃ｡pai Z and Le Cesne A and Novick S and Taningco L and Mo S and Green S and Reichardt P and Demetri GD,Blay,https://pubmed.ncbi.nlm.nih.gov/25882987/,25882987,0.224489796,0.198979592,1.296,0.259282598,0.207971671,0.180381255,0.147724671,0.105393357,0.050357769,0.779166667,0.57035784,1.064420705,0.705814906,0.51736945,0.962899301,0.126036445,0.113655574,1.103924925,0.098871942,0.224599598,0.194509269,0.158816663,0.112301419,0.050226585
795,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Unclear,Phase 2,NCT00719264,RECORD-2,Renal cell cancer,Renal cell cancer,Industry,Novartis Pharmaceuticals,2,1,1,Everolimus plus bevacizumab,Target therapy,Interferon plus bevacizumab,Target therapy and Immune therapy,PFS,RECIST 1.0,182,183,NA,0.9,0.71,1.15,0.91,0.69,1.19,NA,NA,NA,NA,182,49,183,51,27.07,27.14,1.01,0.75,1.34,RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon ﾎｱ-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2015,Ravaud A and Barrios CH and Alekseev B and Tay MH and Agarwala SS and Yalcin S and Lin CC and Roman L and Shkolnik M and Anak O and Gogov S and Pelov D and Louveau AL and Melichar B,Ravaud,https://pubmed.ncbi.nlm.nih.gov/25851632/,25851632,0.112244898,0.12755102,0.989010989,-0.011049836,0.185648878,0.160975839,0.131760903,0.093854411,0.044348871,#VALUE!,#VALUE!,#VALUE!,0.953560372,0.601893321,1.510695253,#VALUE!,0.231837228,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
801,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 2,JapicCTI-121850,No name,Sarcoma,Sarcoma,Industry,"Taiho Pharmaceutical Co., Ltd.",2,≥1,≥1,trabectedin,Chemotherapy,best supportive care,best supportive care,PFS,RECIST 1.1,39,37,8.9,0.13,0.07,0.26,0.07,0.03,0.16,NA,NA,NA,NA,37,3,36,0,NR,8,0.42,0.18,0.98,"Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.",The Lancet. Oncology,54.43,2015,Kawai A and Araki N and Sugiura H and Ueda T and Yonemoto T and Takahashi M and Morioka H and Hiraga H and Hiruma T and Kunisada T and Matsumine A and Tanase T and Hasegawa T and Takahashi S,Kawai,https://pubmed.ncbi.nlm.nih.gov/25795406/,25795406,0.048469388,0.033163265,1.857142857,0.619039208,0.542596117,0.4721625,0.389184156,0.282827133,0.151038709,#VALUE!,#VALUE!,#VALUE!,#DIV/0!,#DIV/0!,#DIV/0!,#VALUE!,#DIV/0!,#VALUE!,#VALUE!,#DIV/0!,#DIV/0!,#DIV/0!,#DIV/0!,#DIV/0!
836,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT00337103,No name,Breast cancer,Breast cancer,Industry,Eisai,2,≥2,≥2,eribulin,Chemotherapy,capecitabine,Chemotherapy,OS and PFS,RECIST 1.0,554,548,NA,0.98,0.86,1.11,1.08,0.93,1.25,554,89,548,109,554,61,548,63,15.9,14.5,0.88,0.77,1,Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2015,Kaufman PA and Awada A and Twelves C and Yelle L and Perez EA and Velikova G and Olivo MS and He Y and Dutcus CE and Cortes J,Kaufman,https://pubmed.ncbi.nlm.nih.gov/25605862/,25605862,0.06377551,0.081632653,0.907407407,-0.097163748,0.099641835,0.086447084,0.070835737,0.050619213,0.024453778,0.770859229,0.566005544,1.049855353,0.952541936,0.655509232,1.384169888,0.123431074,0.18588282,0.809265397,-0.21162836,0.247377082,0.214872041,0.176478235,0.126961178,0.064021867
858,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 2,NCT01081951,No name,Ovarian cancer,Ovarian cancer,Industry,AstraZeneca,2,≥2,≥2,Olaparib plus chemotherapy,Target therapy and chemotherapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,81,81,9.8/7.5,0.61,0.41,0.9,0.51,0.34,0.77,NA,NA,NA,NA,81,52,81,47,33.8,37.6,1.17,0.79,1.73,Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.,The Lancet. Oncology,54.43,2015,Oza AM and Cibula D and Benzaquen AO and Poole C and Mathijssen RH and Sonke GS and Colombo N and ﾅpaﾄ稿k J and Vuylsteke P and Hirte H and Mahner S and Plante M and Schmalfeldt B and Mackay H and Rowbottom J and Lowe ES and Dougherty B and Barrett JC and Friedlander M,Oza,https://pubmed.ncbi.nlm.nih.gov/25481791/,25481791,0.125,0.109693878,1.196078431,0.179048231,0.289334046,0.250602249,0.204667496,0.144831216,0.065160715,#VALUE!,#VALUE!,#VALUE!,1.297138665,0.688568622,2.443574485,#VALUE!,0.447705577,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
893,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT00891579,CTONG0806,Non-small cell lung cancer,Non-small cell lung cancer,Industry and Public,"Guangzhou City, Guangdong Province, Eli Lilly",2,2,2,Pemetrexed,Chemotherapy,gefitinib,Target therapy,PFS,RECIST 1.0,80,81,10.6,0.54,0.4,0.75,0.53,0.38,0.75,76,10,81,11,76,11,81,10,12.4,9.6,0.72,0.49,1.04,Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2014,Zhou Q and Cheng Y and Yang JJ and Zhao MF and Zhang L and Zhang XC and Chen ZH and Yan HH and Song Y and Chen JH and Feng WN and Xu CR and Wang Z and Chen HJ and Zhong WZ and Liu YP and Wu YL,Zhou,https://pubmed.ncbi.nlm.nih.gov/25281710/,25281710,0.089285714,0.094387755,1.018867925,0.018692133,0.236216158,0.204673788,0.167286119,0.11865046,0.05433747,0.964187328,0.384229797,2.419534376,1.201538462,0.478782628,3.015344733,0.519210352,0.64708217,0.802460644,-0.220072467,0.663870871,0.57492904,0.469427596,0.331935437,0.148446043
917,Inclusion,Investigator + Central,No PFS,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT00700336,No name,Pleural mesohelioma,Pleural mesohelioma,Industry,CanBas,2,1,1,Chemotherapy + CBP501,Immunetherapy and Chemotherapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.0,42,23,NA,NA,NA,NA,NA,NA,NA,39,11,20,4,39,12,20,2,13.3,12.8,NA,NA,NA,Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.,"Lung cancer (Amsterdam, Netherlands)",6.08,2014,Krug LM and Wozniak AJ and Kindler HL and Feld R and Koczywas M and Morero JL and Rodriguez CP and Ross HJ and Bauman JE and Orlov SV and Ruckdeschel JC and Mita AC and Fein L and He X and Hall R and Kawabe T and Sharma S,Krug,https://pubmed.ncbi.nlm.nih.gov/25047675/,25047675,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.571428571,0.428769406,5.759244296,4,0.798425161,20.03944864,1.359815023,4.908424357,0.392857143,-0.934309237,1.055958949,0.917957356,0.755143769,0.545745835,0.282693545
937,Inclusion,Investigator + Central,Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,No registry,No name,Head and Neck Cancer,Head and Neck Cancer,Industry,Boehringer Ingelheim,2,≥2,≥2,afatinib,Target therapy,cetuximab,Target therapy,tumor shrinkage,RECIST 1.0,62,62,NA,NA,NA,NA,0.64,0.38,1.05,62,10,62,4,62,5,62,6,35.9,47.1,1.06,0.7,1.62,"A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2014,Seiwert TY and Fayette J and Cupissol D and Del Campo JM and Clement PM and Hitt R and Degardin M and Zhang W and Blackman A and Ehrnrooth E and Cohen EEW,Seiwert,https://pubmed.ncbi.nlm.nih.gov/24928832/,24928832,#VALUE!,0.170918367,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,2.788461538,0.824497717,9.430611618,0.81871345,0.236257319,2.83712571,2.195437219,0.663486834,3.405906593,1.225511158,0.887997645,0.769053589,0.627970562,0.444129072,0.198930933
940,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,No registry,No name,Head and Neck Cancer,Head and Neck Cancer,Industry,Merck-Serono SA,2,2,2,EMD 1201081 and cetuximab,Target therapy,cetuximab,Target therapy,PFS,RECIST 1.0,53,53,NA,1.1,0.7,1.7,1.1,0.7,1.6,53,5,53,6,53,3,53,3,NA,NA,NA,NA,NA,"Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naﾃｯve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).",Investigational new drugs,3.65,2014,Ruzsa A and Sen M and Evans M and Lee LW and Hideghety K and Rottey S and Klimak P and Holeckova P and Fayette J and Csoszi T and Erfan J and Forssmann U and Goddemeier T and Bexon A and Nutting C,Ruzsa,https://pubmed.ncbi.nlm.nih.gov/24894651/,24894651,0.255102041,0.229591837,1,0,0.309368885,0.268032881,0.219030007,0.155263203,0.070800261,0.815972222,0.233047381,2.85697554,1,0.192502917,5.19472649,0.669369428,1.276077442,0.815972222,-0.203374966,1.056145474,0.920168835,0.760248713,0.556098488,0.307017044
959,Inclusion,Investigator + Central,Investigator + Central,Unclear,Central,Unclear,Phase 2,No registry,No name,Breast cancer,Breast cancer,Unclear,,2,≥2,≥2,TSU-68 (orantinib) and Docetaxel,Target therapy and chemotherapy,Docetaxel,Chemotherapy,PFS,RECIST 1.0,40,41,NA,1.2,0.7,2.1,1,0.6,1.8,NA,NA,NA,NA,38,19,39,16,29,26,0.8,0.5,1.6,"Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.",Investigational new drugs,3.65,2014,Kim SB and Yoo C and Ro J and Im SA and Im YH and Kim JH and Ahn JH and Jung KH and Song HS and Kang SY and Park HS and Chung HC,Kim,https://pubmed.ncbi.nlm.nih.gov/24715580/,24715580,0.357142857,0.306122449,1.2,0.182321557,0.396345,0.343244838,0.280258237,0.1981725,0.088625436,#VALUE!,#VALUE!,#VALUE!,1.4375,0.583955646,3.538635624,#VALUE!,0.753744892,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
981,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT00705016,ADVANTAGE,Head and Neck Cancer,Head and Neck Cancer,Industry,Merck KGaA,3,≥1,≥1,"cilengitide 2000 mg once (CIL1W) and PFE (Cisplatin, 5-fluorouracil, and cetuximab)",Chemotherapy,"PFE (Cisplatin, 5-fluorouracil, and cetuximab)",Chemotherapy,PFS,RECIST 1.0,62,62,NA,1.03,0.67,1.59,1.15,0.74,1.79,62,29,62,22,62,26,62,20,12.4,11.6,0.94,0.61,1.47,"Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).",Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2014,Vermorken JB and Peyrade F and Krauss J and Mesﾃｭa R and Remenar E and Gauler TC and Keilholz U and Delord JP and Schafhausen P and Erfﾃ｡n J and Brﾃｼmmendorf TH and Iglesias L and Bethe U and Hicking C and Clement PM,Vermorken,https://pubmed.ncbi.nlm.nih.gov/24567516/,24567516,0.234693878,0.267857143,0.895652174,-0.11020314,0.315246381,0.273022254,0.222939503,0.157679716,0.070651181,1.597796143,0.777116149,3.285162092,1.516666667,0.728346915,3.158217231,0.639807638,0.619864876,1.053491963,0.052110325,0.524680069,0.454397822,0.371033134,0.262400062,0.117491946
984,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01223027,GOLD,Renal cell cancer,Renal cell cancer,Industry,Novartis Pharmaceuticals Corporation,3,3,3,Dovitinib,Target therapy,sorafenib,Target therapy,PFS,RECIST 1.1,284,286,11.3,1,0.82,1.21,0.86,0.72,1.04,284,18,286,11,284,11,286,11,11.1,11,0.96,0.75,1.22,"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.",The Lancet. Oncology,54.43,2014,Motzer RJ and Porta C and Vogelzang NJ and Sternberg CN and Szczylik C and Zolnierek J and Kollmannsberger C and Rha SY and Bjarnason GA and Melichar B and De Giorgi U and Grﾃｼnwald V and Davis ID and Lee JL and Esteban E and Urbanowitz G and Cai C and Squires M and Marker M and Shi MM and Escudier B,Motzer,https://pubmed.ncbi.nlm.nih.gov/24556040/,24556040,0.099489796,0.081632653,1.162790698,0.15082289,0.136568488,0.118303117,0.096645243,0.068446902,0.030995464,1.691729323,0.78422478,3.649397694,1.007326007,0.429532191,2.362350729,0.730911458,0.493065953,1.679425837,0.518451972,0.5856432,0.507629504,0.415207741,0.295139329,0.137386418
987,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Unclear,Phase 3,NCT00796120,No name,Sarcoma,Sarcoma,Industry,PharmaMar,2,1,1,trabectedin,Chemotherapy,doxorubicin-base chemotherapy,Chemotherapy,PFS,RECIST 1.0,61,60,17.6,0.85,0.5,1.5,0.84,0.4,1.8,NA,NA,NA,NA,51,3,37,10,NA,NA,0.77,0.4,1.4,Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.,"European journal of cancer (Oxford, England : 1990)",10.00,2014,Blay JY and Leahy MG and Nguyen BB and Patel SR and Hohenberger P and Santoro A and Staddon AP and Penel N and Piperno-Neumann S and Hendifar A and Lardelli P and Nieto A and Alfaro V and Chawla SP,Blay,https://pubmed.ncbi.nlm.nih.gov/24512981/,24512981,0.255102041,0.357142857,1.011904762,0.011834458,0.475147515,0.414727103,0.343848772,0.253900347,0.146465398,#VALUE!,#VALUE!,#VALUE!,0.16875,0.042722862,0.666541552,#VALUE!,0.159137421,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
993,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01121393,LUX-Lung 6,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Boehringer Ingelheim,2,1,1,Afatinib,Target therapy,cisplatin plus gemcitabine,Chemotherapy,PFS,RECIST 1.1,242,122,16.6,0.26,0.19,0.36,0.28,0.2,0.39,242,180,122,38,242,162,122,28,22.1,22.2,0.95,0.68,1.33,"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.",The Lancet. Oncology,54.43,2014,Wu YL and Zhou C and Hu CP and Feng J and Lu S and Huang Y and Li W and Hou M and Shi JH and Lee KY and Xu CR and Massey D and Kim M and Shi Y and Geater SL,Wu,https://pubmed.ncbi.nlm.nih.gov/24439929/,24439929,0.043367347,0.048469388,0.928571429,-0.074107972,0.235803067,0.204244368,0.166818576,0.118072489,0.05320952,6.417657046,3.972250409,10.36851097,6.798214286,4.124143437,11.20613727,1.631699124,1.806631079,0.944021,-0.057606868,0.353455177,0.306144026,0.250035531,0.176950189,0.079663361
1014,Inclusion,Investigator + Central,Investigator + Central,Unclear,Central,Blinding,Phase 3,NCT00474786,INTORSECT,Renal cell cancer,Renal cell cancer,Industry,Pfizer Inc,2,2,2,Temsirolimus,Target therapy,Sorafenib,Target therapy,PFS,RECIST 1.0,259,253,9.2,0.87,0.7,1.07,0.87,0.71,1.07,NA,NA,NA,NA,259,20,253,20,12.3,16.6,1.31,1.05,1.63,Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2014,Hutson TE and Escudier B and Esteban E and Bjarnason GA and Lim HY and Pittman KB and Senico P and Niethammer A and Lu DR and Hariharan S and Motzer RJ,Hutson,https://pubmed.ncbi.nlm.nih.gov/24297950/,24297950,0.094387755,0.091836735,1,0,0.150549365,0.130392127,0.106485222,0.075339884,0.033848111,#VALUE!,#VALUE!,#VALUE!,0.974895397,0.511215243,1.859140643,#VALUE!,0.34385852,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1015,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT00631371,INTORACT,Renal cell cancer,Renal cell cancer,Industry,Pfizer Inc,2,1,1,Temsirolimus and Bevacizumab,Target therapy,Interferon Alfa and Bevacizumab,Immunotherapy and Target therapy,PFS,RECIST 1.0,400,391,NA,1.1,1,1.4,1.1,0.9,1.3,NA,NA,NA,NA,400,108,391,107,25.8,25.5,1,0.9,1.3,Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2014,Rini BI and Bellmunt J and Clancy J and Wang K and Niethammer AG and Hariharan S and Escudier B,Rini,https://pubmed.ncbi.nlm.nih.gov/24297945/,24297945,0.102040816,0.102040816,1,0,0.127151179,0.110188281,0.090086027,0.063949411,0.029474653,#VALUE!,#VALUE!,#VALUE!,0.981692485,0.717648123,1.342886721,#VALUE!,0.159499642,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1022,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Unclear,Phase 3,NCT00095199,No name,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Eli Lilly and Company and ImClone Systems LLC,2,2,2,Cetuximab plus pemetrexed,Target therapy and chemotherapy,pemetrexed,Chemotherapy,PFS,WHO criteria,301,304,NA,0.94,0.8,1.11,1.03,0.87,1.21,NA,NA,NA,NA,301,20,304,13,6.9,7.8,1.01,0.86,1.2,"Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.",The Lancet. Oncology,54.43,2013,Kim ES and Neubauer M and Cohn A and Schwartzberg L and Garbo L and Caton J and Robert F and Reynolds C and Katz T and Chittoor S and Simms L and Saxman S,Kim,https://pubmed.ncbi.nlm.nih.gov/24231627/,24231627,0.079081633,0.086734694,0.912621359,-0.091434206,0.118582943,0.10269629,0.083851901,0.059293801,0.026522548,#VALUE!,#VALUE!,#VALUE!,1.593211059,0.777627762,3.264185777,#VALUE!,0.634326024,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1032,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT00844649,No name,Pancretic cancer,Pancretic cancer,Industry,Celgene,2,1,1,nab-Paclitaxel plus Gemcitabine,Chemotherapy,Gemcitabine,Chemotherapy,OS,RECIST 1.0,431,430,9.1/7.4,0.61,0.52,0.71,0.69,0.58,0.82,431,126,430,33,431,99,430,31,8.5,6.7,0.72,0.62,0.83,Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.,The New England journal of medicine,176.08,2013,Von Hoff DD and Ervin T and Arena FP and Chiorean EG and Infante J and Moore M and Seay T and Tjulandin SA and Ma WW and Saleh MN and Harris M and Reni M and Dowden S and Laheru D and Bahary N and Ramanathan RK and Tabernero J and Hidalgo M and Goldstein D and Van Cutsem E and Wei X and Iglesias J and Renschler MF,Von,https://pubmed.ncbi.nlm.nih.gov/24131140/,24131140,0.048469388,0.06122449,0.884057971,-0.12323264,0.118807381,0.102986132,0.084244247,0.059900274,0.027942845,4.969895678,3.293966302,7.498517225,3.838029538,2.499506741,5.893351071,1.072589521,0.865776615,1.294908137,0.258439756,0.303174054,0.26259464,0.214470006,0.151785446,0.068351828
1033,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator,Blinding,Phase 2,NCT00722592,PRECEDENT,Ovarian cancer,Ovarian cancer,Industry,Endocyte,2,≥2,≥2,Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD),Chemotherapy,Pegylated Liposomal Doxorubicin (PLD),Chemotherapy,PFS,RECIST 1.0,109,53,NA,0.626,0.409,0.959,0.768,0.499,1.182,,18%,,12%,NA,NA,NA,NA,16.8,NA,1.01,0.679,1.503,PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2013,Naumann RW and Coleman RL and Burger RA and Sausville EA and Kutarska E and Ghamande SA and Gabrail NY and Depasquale SE and Nowara E and Gilbert L and Gersh RH and Teneriello MG and Harb WA and Konstantinopoulos PA and Penson RT and Symanowski JT and Lovejoy CD and Leamon CP and Morgenstern DE and Messmann RA,Naumann,https://pubmed.ncbi.nlm.nih.gov/24127448/,24127448,0.140306122,0.174234694,0.815104167,-0.204439362,0.309280434,0.267847861,0.218702003,0.154656574,0.069203524,1,1,1,#VALUE!,#VALUE!,#VALUE!,0,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1043,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01030783,No name,Renal cell cancer,Renal cell cancer,Industry,AVEO Oncology and Astellas,2,≥1,≥1,Tivozanib,Target therapy,Sorafenib,Target therapy,PFS,RECIST 1.0,260,257,NA,0.722,0.58,0.899,0.797,0.639,0.993,260,92,257,79,260,86,257,60,29.3,28.8,1.245,0.954,1.624,Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2013,Motzer RJ and Nosov D and Eisen T and Bondarenko I and Lesovoy V and Lipatov O and Tomczak P and Lyulko O and Alyasova A and Harza M and Kogan M and Alekseev BY and Sternberg CN and Szczylik C and Cella D and Ivanescu C and Krivoshik A and Strahs A and Esteves B and Berkenblit A and Hutson TE,Motzer,https://pubmed.ncbi.nlm.nih.gov/24019545/,24019545,0.081377551,0.090306122,0.905897114,-0.09882954,0.158573187,0.1373288,0.112129135,0.079288629,0.035463806,1.233875829,0.85467336,1.781323289,1.622796935,1.101307198,2.391221902,0.236390288,0.329059874,0.760339019,-0.273990868,0.272426125,0.235985656,0.192775687,0.136512642,0.061759939
1051,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT00246571,No name,Breast cancer,Breast cancer,Industry,Pfizer Inc,2,"2, 3",≥2,sunitinib,Target therapy,Standard care,Chemotherapy,PFS,RECIST 1.0,113,104,15.8/16.2,1.16,0.87,1.55,1.2,0.89,1.63,113,10,104,12,113,3,104,7,9.4,10.5,1.16,0.86,1.56,Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.,"Breast (Edinburgh, Scotland)",4.25,2013,Curigliano G and Pivot X and Cortﾃｩs J and Elias A and Cesari R and Khosravan R and Collier M and Huang X and Cataruozolo PE and Kern KA and Goldhirsch A,Curigliano,https://pubmed.ncbi.nlm.nih.gov/23958375/,23958375,0.173469388,0.18877551,0.966666667,-0.033901552,0.213386206,0.184831397,0.150968928,0.106867158,0.048205469,0.74433657,0.307177089,1.803640141,0.377922078,0.095095657,1.501909776,0.381750778,0.358881153,1.969550373,0.67780528,0.836362541,0.735224602,0.617744389,0.471869733,0.309036207
1061,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00435409,No name,Breast cancer,Breast cancer,Industry,Pfizer Inc,2,≥2,≥2,Sunitinib and Capecitabine,Target therapy and chemotherapy,Capecitabine,Chemotherapy,PFS,RECIST 1.0,221,221,14.3,1.11,0.88,1.39,1.22,0.95,1.58,221,56,221,45,221,40,221,36,16.4,16.5,0.99,0.76,1.3,Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2013,Crown JP and Diﾃｩras V and Staroslawska E and Yardley DA and Bachelot T and Davidson N and Wildiers H and Fasching PA and Capitain O and Ramos M and Greil R and Cognetti F and Fountzilas G and Blasinska-Morawiec M and Liedtke C and Kreienberg R and Miller WH Jr and Tassell V and Huang X and Paolini J and Kern KA and Romieu G,Crown,https://pubmed.ncbi.nlm.nih.gov/23857972/,23857972,0.130102041,0.160714286,0.909836066,-0.094490843,0.174473477,0.151241633,0.123721741,0.087977876,0.041067464,1.327407407,0.849629836,2.07385658,1.135666053,0.692467784,1.862523301,0.312302741,0.29848355,1.168836036,0.156008413,0.3398968,0.294619495,0.240980205,0.171295859,0.079742845
1068,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00949650,LUX-Lung 3,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Boehringer Ingelheim,2,1,1,Afatinib,Target therapy,Cisplatin Plus Pemetrexed,Chemotherapy,PFS,RECIST 1.1,230,115,16.4,0.49,0.37,0.65,0.58,0.43,0.78,155,107,83,37,152,85,69,16,16.6,14.8,1.12,0.73,1.73,Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2013,Sequist LV and Yang JC and Yamamoto N and O'Byrne K and Hirsh V and Mok T and Geater SL and Orlov S and Tsai CM and Boyer M and Su WC and Bennouna J and Kato T and Gorbunova V and Lee KH and Shah R and Massey D and Zazulina V and Shahidi M and Schuler M,Sequist,https://pubmed.ncbi.nlm.nih.gov/23816960/,23816960,0.071428571,0.089285714,0.844827586,-0.168622712,0.209141413,0.181167874,0.147998198,0.104809994,0.047439111,2.771396396,1.597829453,4.80691977,4.202425373,2.20641087,8.004120744,0.818645489,1.479007621,0.659475458,-0.416310521,0.432438769,0.375263209,0.307638852,0.220138252,0.107313559
1097,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT00391092,AVEREL,Breast cancer,Breast cancer,Industry,F. Hoffmann-La Roche,2,1,1,Bevacizumab and Docetaxel and Trastuzumab,Target therapy and chemotherapy,Docetaxel and Trastuzumab,Target therapy and Chemotherapy,PFS,RECIST 1.0,216,208,26,0.82,0.65,1.02,0.72,0.54,0.94,NA,74.30%,NA,69.90%,NA,76.50%,NA,65.90%,>38,>38,1.01,0.74,1.38,AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2013,Gianni L and Romieu GH and Lichinitser M and Serrano SV and Mansutti M and Pivot X and Mariani P and Andre F and Chan A and Lipatov O and Chan S and Wardley A and Greil R and Moore N and Prot S and Pallaud C and Semiglazov V,Gianni,https://pubmed.ncbi.nlm.nih.gov/23569311/,23569311,0.094387755,0.102040816,1.138888889,0.130053128,0.182230679,0.158369994,0.13020787,0.093952775,0.048223973,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1144,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Unclear,Phase 3,NCT00829166,EMILIA,Breast cancer,Breast cancer,Industry,F Hoffmann-La Roche/Genentech.,2,≥2,≥2,trastuzumab emtansine,Target therapy,Lapatinib and Capecitabine,Target therapy and chemotherapy,OS and PFS,RECIST 1.1,495,496,19,0.66,0.56,0.77,0.65,0.55,0.77,NA,NA,NA,NA,397,173,389,120,30.9,25.1,0.68,0.55,0.85,Trastuzumab emtansine for HER2-positive advanced breast cancer.,The New England journal of medicine,176.08,2012,Verma S and Miles D and Gianni L and Krop IE and Welslau M and Baselga J and Pegram M and Oh DY and Diﾃｩras V and Guardino E and Fang L and Lu MW and Olsen S and Blackwell K,Verma,https://pubmed.ncbi.nlm.nih.gov/23020162/,23020162,0.053571429,0.056122449,1.015384615,0.015267472,0.118183119,0.102375384,0.083631268,0.05922549,0.026803627,#VALUE!,#VALUE!,#VALUE!,1.731287202,1.29201718,2.319903653,#VALUE!,0.262215937,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1145,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Unclear,Phase 2,NCT01072175,No name,Melanoma,Melanoma,Industry,GlaxoSmithKline,3,≥1,≥1,Dabrafenib (150mg) and trametinib (2mg),Target therapy,Dabrafenib,Target therapy,"incidence of cutaneous squamous-cell carcinoma, progression-free survival, response rate, duration of response, and safety.",RECIST 1.1,54,54,14.1,0.39,0.25,0.62,0.55,0.33,0.93,54,41,54,29,NA,NA,NA,NA,NR,NR,0.67,0.34,1.34,Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.,The New England journal of medicine,176.08,2012,Flaherty KT and Infante JR and Daud A and Gonzalez R and Kefford RF and Sosman J and Hamid O and Schuchter L and Cebon J and Ibrahim N and Kudchadkar R and Burris HA 3rd and Falchook G and Algazi A and Lewis K and Long GV and Puzanov I and Lebowitz P and Singh A and Little S and Sun P and Allred A and Ouellet D and Kim KB and Patel K and Weber J,Flaherty,https://pubmed.ncbi.nlm.nih.gov/23020132/,23020132,0.094387755,0.153061224,0.709090909,-0.343771539,0.35148767,0.304833641,0.249606721,0.177998544,0.084778859,2.718832891,1.195318958,6.184167197,#VALUE!,#VALUE!,#VALUE!,1.272665367,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1150,Inclusion,Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00262990,No name,"Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer",Ovarian cancer,Industry,Novartis Pharmaceuticals,2,≥2,≥2,Patupilone,Chemotherapy,Pegylated Liposomal Doxorubicin,Chemotherapy,OS,RECIST 1.0 or 1.1,412,417,27,0.99,0.84,1.16,1.05,0.89,1.24,412,73,416,36,412,64,416,33,13.2,12.7,0.93,0.79,1.09,"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2012,Colombo N and Kutarska E and Dimopoulos M and Bae DS and Rzepka-Gorska I and Bidzinski M and Scambia G and Engelholm SA and Joly F and Weber D and El-Hashimy M and Li J and Souami F and Wing P and Engelholm S and Bamias A and Schwartz P,Colombo,https://pubmed.ncbi.nlm.nih.gov/22987083/,22987083,0.081632653,0.089285714,0.942857143,-0.0588405,0.11805774,0.102247264,0.083494767,0.059061401,0.026490518,2.273025238,1.485768871,3.477420903,2.134447928,1.368603682,3.328843854,0.508074498,0.500061268,1.064924193,0.062903617,0.313799935,0.271803024,0.221998578,0.157130052,0.070816954
1178,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT01227889,No name,Melanoma,Melanoma,Industry,GlaxoSmithKline,2,≥1,≥1,dabrafenib,Target therapy,dacarbazine,Chemotherapy,PFS,RECIST 1.1,187,63,4.9,0.3,0.18,0.51,0.35,0.2,0.61,187,99,63,12,187,93,63,4,NR,NR,0.61,0.25,1.48,"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","Lancet (London, England)",202.73,2012,Hauschild A and Grob JJ and Demidov LV and Jouary T and Gutzmer R and Millward M and Rutkowski P and Blank CU and Miller WH Jr and Kaempgen E and Martﾃｭn-Algarra S and Karaszewska B and Mauch C and Chiarion-Sileni V and Martin AM and Swann S and Haney P and Mirakhur B and Guckert ME and Goodman V and Chapman PB,Hauschild,https://pubmed.ncbi.nlm.nih.gov/22735384/,22735384,0.084183673,0.104591837,0.857142857,-0.15415068,0.389243162,0.337225473,0.275557253,0.195301255,0.088944952,4.78125,2.395007374,9.54500258,14.59308511,5.094087053,41.80496539,1.823978369,9.365019983,0.327638054,-1.115845775,0.642453081,0.563957005,0.472598185,0.358678945,0.229982214
1187,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator,Blinding,Phase 3,NCT01245062,METRIC,Melanoma,Melanoma,Industry,GlaxoSmithKline,2,≥1,≥1,Trametinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,214,108,NA,0.45,0.33,0.63,0.42,0.29,0.59,214,47,108,9,NA,NA,NA,NA,NR,NR,0.54,0.32,0.92,Improved survival with MEK inhibition in BRAF-mutated melanoma.,The New England journal of medicine,176.08,2012,Flaherty KT and Robert C and Hersey P and Nathan P and Garbe C and Milhem M and Demidov LV and Hassel JC and Rutkowski P and Mohr P and Dummer R and Trefzer U and Larkin JM and Utikal J and Dreno B and Nyakas M and Middleton MR and Becker JC and Casey M and Sherman LJ and Wu FS and Ouellet D and Martin AM and Patel K and Schadendorf D,Flaherty,https://pubmed.ncbi.nlm.nih.gov/22663011/,22663011,0.076530612,0.076530612,1.071428571,0.068992871,0.245026784,0.212354496,0.173639682,0.123316854,0.057027118,3.095808383,1.454712867,6.58826203,#VALUE!,#VALUE!,#VALUE!,1.309578868,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1191,Inclusion,Investigator + Central,Investigator,Investigator + Central,Investigator + Central,Unclear,Phase 2,NA,No name,Colorectal cancer,Colorectal cancer,Unclear,,2,1,1,Leucovorin Na,Chemotherapy,Leucovorin Ca,Chemotherapy,ORR,RECIST 1.0,28,29,21.2,0.62,0.33,1.14,NA,NA,NA,22,16,19,12,22,13,19,15,22.9,11.9,0.43,0.2,0.91,A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.,Acta gastro-enterologica Belgica,1.69,2012,Bleiberg H and Vandebroek A and Deleu I and Vergauwe P and Rezaei Kalantari H and D'Haens G and Paesmans M and Peeters M and Efira A and Humblet Y,Bleiberg,https://pubmed.ncbi.nlm.nih.gov/22567742/,22567742,0.206632653,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.555555556,0.414460211,5.838324215,0.385185185,0.095707352,1.550221838,1.383638777,0.371049614,4.038461538,1.395863812,0.979825493,0.848740667,0.693298956,0.490883046,0.221829537
1198,Inclusion,Central,Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NA,No name,Non-small cell lung cancer,Non-small cell lung cancer,Industry,"Celgene, Summit",2,1,1,nab-Paclitaxel and Carboplatin,Chemotherapy,Solvent-Based Paclitaxel and Carboplatin,Chemotherapy,ORR,RECIST 1.0,521,531,NA,NA,NA,NA,0.902,0.767,1.06,521,198,531,159,521,170,531,132,12.1,11.2,0.922,0.797,1.066,Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2012,Socinski MA and Bondarenko I and Karaseva NA and Makhson AM and Vynnychenko I and Okamoto I and Hon JK and Hirsh V and Bhar P and Zhang H and Iglesias JL and Renschler MF,Socinski,https://pubmed.ncbi.nlm.nih.gov/22547591/,22547591,#VALUE!,0.074744898,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.434195923,1.109735389,1.853521087,1.463998964,1.118886998,1.915558024,0.18974125,0.203232404,0.979642717,-0.020567348,0.189571463,0.164203951,0.134121347,0.094942792,0.042832374
1218,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Blinding,Phase 3,NA,ENEST g3,Gastrointestinal stromal tumours,Gastrointestinal stromal tumours,Industry,Novartis Pharm,2,≥2,≥2,nilotinib,Target therapy,BSC ± imanitib/sunitinib,BSC ± target therapy,PFS,RECIST 1.0,165,83,NA,0.58,0.42,0.8,0.9,0.65,1.26,NA,NA,NA,NA,163,1,83,0,11.06666667,9.333333333,0.79,0.52,1.22,Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2012,Reichardt P and Blay JY and Gelderblom H and Schlemmer M and Demetri GD and Bui-Nguyen B and McArthur GA and Yazji S and Hsu Y and Galetic I and Rutkowski P,Reichardt,https://pubmed.ncbi.nlm.nih.gov/22357255/,22357255,0.096938776,0.155612245,0.644444444,-0.43936666,0.235648634,0.204089963,0.166658775,0.117888004,0.05287276,#VALUE!,#VALUE!,#VALUE!,#DIV/0!,#DIV/0!,#DIV/0!,#VALUE!,#DIV/0!,#VALUE!,#VALUE!,#DIV/0!,#DIV/0!,#DIV/0!,#DIV/0!,#DIV/0!
1220,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NA,No name,Breast cancer,Breast cancer,Industry,Pfizer Inc,2,1,1,Sunitinib and Docetaxel,Target therapy and chemotherapy,Docetaxel,Chemotherapy,PFS,RECIST 1.0,296,297,18,0.86,0.69,1.06,0.92,0.72,1.19,296,156,297,130,296,148,297,113,24.8,25.5,1.21,0.91,1.6,"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2012,Bergh J and Bondarenko IM and Lichinitser MR and Liljegren A and Greil R and Voytko NL and Makhson AN and Cortes J and Lortholary A and Bischoff J and Chan A and Delaloge S and Huang X and Kern KA and Giorgetti C,Bergh,https://pubmed.ncbi.nlm.nih.gov/22331954/,22331954,0.094387755,0.119897959,0.934782609,-0.067441281,0.168597146,0.146307019,0.119943695,0.085832605,0.041854904,1.431428571,1.035850461,1.978072928,1.628318584,1.174406892,2.25766847,0.240362874,0.276342239,0.879083851,-0.128874992,0.234587508,0.203160522,0.16588278,0.117303007,0.052481565
1249,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00678392,AXIS,Renal cell cancer,Renal cell cancer,Industry,Pfizer Inc,2,2,2,axitinib,Target therapy,sorafenib,Target therapy,PFS,RECIST 1.0,361,362,NA,0.658,0.543,0.798,0.665,0.544,0.812,361,70,362,40,361,70,362,34,20.1,19.2,0.969,0.8,1.174,Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.,"Lancet (London, England)",202.73,2011,Rini BI and Escudier B and Tomczak P and Kaprin A and Szczylik C and Hutson TE and Michaelson MD and Gorbunova VA and Gore ME and Rusakov IG and Negrier S and Ou YC and Castellano D and Lim HY and Uemura H and Tarazi J and Cella D and Chen C and Rosbrook B and Kim S and Motzer RJ,Rini,https://pubmed.ncbi.nlm.nih.gov/22056247/,22056247,0.06505102,0.068367347,0.989473684,-0.010582109,0.141728785,0.122756756,0.100256641,0.070947634,0.031926555,1.936426117,1.272850386,2.945944117,2.320598342,1.495941553,3.599857665,0.426809625,0.536713294,0.83445122,-0.180980992,0.309855476,0.268388742,0.219213635,0.155166745,0.069959984
1290,Inclusion,Investigator,No PFS,Investigator + Central,Investigator + Central,Unclear,Phase 2,NCT00227630,EORTC 08062,Small-cell lung cancer,Small-cell lung cancer,Industry and Public,Celgene Inc and UK NHS funding,3,1,1,Amrubicin,Chemotherapy,Cisplatin + etoposide,Chemotherapy,ORR,RECIST 1.0,33,33,17.4,No HR,No HR,No HR,No HR,No HR,No HR,28,17,30,19,28,17,30,20,11.1,10,No HR,No HR,No HR,Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.,"European journal of cancer (Oxford, England : 1990)",10.00,2011,O'Brien ME and Konopa K and Lorigan P and Bosquee L and Marshall E and Bustin F and Margerit S and Fink C and Stigt JA and Dingemans AM and Hasan B and Van Meerbeeck J and Baas P,O'Brien,https://pubmed.ncbi.nlm.nih.gov/21684151/,21684151,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.894736842,0.30954308,2.586244265,0.772727273,0.264242824,2.259692165,0.580791119,0.509043199,1.157894737,0.146603474,0.77006877,0.666905711,0.544537001,0.385068647,0.17228963
1297,Inclusion,Unclear,No PFS,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00019682,No name,Melanoma,Melanoma,Public,National Cancer Institute,2,≥1,≥1,gp100 Peptide Vaccine and Interleukin-2,Immunotherapy,Interleukin-2,Immunotherapy,ORR,WHO criteria,91,94,41.5,No HR,No HR,No HR,No HR,No HR,No HR,85,17,93,9,85,14,93,6,17.8,11.1,No HR,No HR,No HR,gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.,The New England journal of medicine,176.08,2011,Schwartzentruber DJ and Lawson DH and Richards JM and Conry RM and Miller DM and Treisman J and Gailani F and Riley L and Conlon K and Pockaj B and Kendra KL and White RL and Gonzalez R and Kuzel TM and Curti B and Leming PD and Whitman ED and Balkissoon J and Reintgen DS and Kaufman H and Marincola FM and Merino MJ and Rosenberg SA and Choyke P and Vena D and Hwu P,Schwartzentruber,https://pubmed.ncbi.nlm.nih.gov/21631324/,21631324,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,2.333333333,0.978595077,5.563531404,2.85915493,1.045067891,7.822235265,1.169626614,1.728869228,0.816091954,-0.203228242,0.678394636,0.5885533,0.482255836,0.34459599,0.166393989
1304,Inclusion,Investigator + Central,Central,Investigator + Central,Investigator + Central,Unclear,Phase 2,NA,HERTAX,Breast cancer,Breast cancer,Industry,Sanofi-Aventis and Roche,2,1,1,Trastuzumab Followed by Docetaxel,Target therapy and chemotherapy,Trastuzumab and Docetaxel,Target therapy and Chemotherapy,PFS,RECIST 1.0,46,55,NA,No HR,No HR,No HR,1.33,0.86,2.06,46,24,53,42,46,19,53,38,19.7,30.5,1.49,0.91,2.47,Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.,Clinical breast cancer,3.08,2011,Hamberg P and Bos MM and Braun HJ and Stouthard JM and van Deijk GA and Erdkamp FL and van der Stelt-Frissen IN and Bontenbal M and Creemers GJ and Portielje JE and Pruijt JF and Loosveld OJ and Smit WM and Muller EW and Schmitz PI and Seynaeve C and Klijn JG,Hamberg,https://pubmed.ncbi.nlm.nih.gov/21569996/,21569996,#VALUE!,0.306122449,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.285714286,0.118442924,0.689215109,0.277777778,0.120200668,0.641930659,0.145605149,0.133094385,1.028571429,0.028170877,0.620073301,0.537110748,0.438731138,0.310615627,0.140284401
1329,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Blinding,Phase 3,NCT00388726,EMBRACE,Breast cancer,Breast cancer,Industry,Eisai,2,≥2,≥2,eribulin mesilate,Chemotherapy,treatment of physician’s choice (TPC),Chemotherapy,OS,RECIST 1.0,508,254,NA,0.76,0.64,0.9,0.87,0.71,1.05,468,62,214,16,468,57,214,10,13.1,10.6,0.81,0.66,0.99,Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.,"Lancet (London, England)",202.73,2011,Cortes J and O'Shaughnessy J and Loesch D and Blum JL and Vahdat LT and Petrakova K and Chollet P and Manikas A and Diﾃｩras V and Delozier T and Vladimirov V and Cardoso F and Koh H and Bougnoux P and Dutcus CE and Seegobin S and Mir D and Meneses N and Wanders J and Twelves C,Cortes,https://pubmed.ncbi.nlm.nih.gov/21376385/,21376385,0.066326531,0.086734694,0.873563218,-0.135174778,0.132390671,0.114833437,0.094053957,0.067123582,0.032142154,1.889778325,1.063109807,3.359259874,2.82919708,1.415331859,5.655462404,0.585752568,1.081665955,0.667955703,-0.40353342,0.459370767,0.398951846,0.327572357,0.235467031,0.11814221
1426,Inclusion,Investigator + Central,No PFS,Investigator + Central,Investigator + Central,Unclear,Phase 2,NA,No name,Non-small cell lung cancer,Non-small cell lung cancer,Unclear,,2,2,2,BI 2536 day 1 dose,Target therapy,BI 2536 days 1-3 dose,Target therapy,ORR,RECIST 1.0,48,47,NA,No HR,No HR,No HR,No HR,No HR,No HR,48,3,47,1,48,2,47,0,237 days,244 days,No HR,No HR,No HR,"The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.",Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,20.12,2010,Sebastian M and Reck M and Waller CF and Kortsik C and Frickhofen N and Schuler M and Fritsch H and Gaschler-Markefski B and Hanft G and Munzert G and von Pawel J,Sebastian,https://pubmed.ncbi.nlm.nih.gov/20526206/,20526206,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,3.066666667,0.307392605,30.59424425,4.086956522,0.179439021,93.08573767,7.726237663,23.70058639,0.75035461,-0.287209371,1.980035149,1.727643232,1.431419952,1.055071099,0.603775272
1431,Inclusion,Investigator + Central,Investigator + Central,Central,Investigator + Central,Blinding,Phase 3,NA,No name,Ovarian cancer,Ovarian cancer,Industry,Johnson & Johnson,2,2,2,Trabectedin Plus Pegylated Liposomal Doxorubicin,Chemotherapy,Pegylated Liposomal Doxorubicin,Chemotherapy,PFS,RECIST 1.0,337,335,17,0.72,0.61,0.86,0.79,0.65,0.96,337,130,335,89,337,93,335,63,20.5,19.4,0.85,0.67,1.06,Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2010,Monk BJ and Herzog TJ and Kaye SB and Krasner CN and Vermorken JB and Muggia FM and Pujade-Lauraine E and Lisyanskaya AS and Makhson AN and Rolski J and Gorbounova VA and Ghatage P and Bidzinski M and Shen K and Ngan HY and Vergote IB and Nam JH and Park YC and Lebedinsky CA and Poveda AM,Monk,https://pubmed.ncbi.nlm.nih.gov/20516432/,20516432,0.06377551,0.079081633,0.911392405,-0.092781733,0.132565591,0.114958193,0.094112361,0.067073742,0.031816459,1.735873636,1.251785814,2.407166823,1.645589383,1.144044664,2.367009351,0.294740053,0.311980787,1.054864387,0.053412216,0.249448906,0.21623064,0.176880251,0.125767867,0.058671142
1454,Inclusion,Investigator + Central,No PFS,Investigator + Central,Investigator + Central,Blinding,Phase 2,NCT00073008,No name,Non-small cell lung cancer,Non-small cell lung cancer,Industry,GlaxoSmithKline,2,"1, 2",≥1,Lapatinib 1500mg,Target therapy,Lapatinib 500mg,Target therapy,ORR,RECIST 1.0,65,66,NA,NA,NA,NA,No HR,No HR,No HR,65,1,66,1,65,1,66,0,14.5,11.3,No HR,No HR,No HR,Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.,Clinical cancer research : an official journal of the American Association for           Cancer Research,13.80,2010,Ross HJ and Blumenschein GR Jr and Aisner J and Damjanov N and Dowlati A and Garst J and Rigas JR and Smylie M and Hassani H and Allen KE and Leopold L and Zaks TZ and Shepherd FA,Ross,https://pubmed.ncbi.nlm.nih.gov/20215545/,20215545,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,1.015625,0.06217761,16.5894787,2.0625,0.067994064,62.56290617,4.216148238,15.94257962,0.492424242,-0.708414653,2.249867061,1.954830034,1.606492805,1.157703678,0.58978364
1466,Inclusion,Investigator + Central,Investigator + Central,Investigator,Investigator,Unclear,Phase 3,NCT00320385,EGF104900,Breast cancer,Breast cancer,Industry,GlaxoSmithKline,2,≥2,≥2,Trastuzumab and Lapatinib,Target therapy,Lapatinib,Target therapy,PFS,RECIST 1.0,148,148,NA,0.73,0.57,0.93,0.71,0.52,0.98,146,15,145,10,NA,NA,NA,NA,51.6 weeks,39.0 weeks,0.75,0.53,1.07,"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2010,Blackwell KL and Burstein HJ and Storniolo AM and Rugo H and Sledge G and Koehler M and Ellis C and Casey M and Vukelja S and Bischoff J and Baselga J and O'Shaughnessy J,Blackwell,https://pubmed.ncbi.nlm.nih.gov/20124187/,20124187,0.091836735,0.117346939,1.028169014,0.027779564,0.204282947,0.177867435,0.146772362,0.106992653,0.058066077,1.545801527,0.67035343,3.564541109,#VALUE!,#VALUE!,#VALUE!,0.738313183,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1468,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NA,BMS099,Non-small cell lung cancer,Non-small cell lung cancer,Industry,"by Bristol-Myers Squibb and ImClone Systems Inc, a wholly owned subsidiary of Eli Lilly.",2,1,1,Cetuximab and Taxane/Carboplatin,Target therapy and chemotherapy,Taxane/Carboplatin,Chemotherapy,PFS,WHO criteria,338,338,NA,0.766,0.649,0.903,0.902,0.761,1.069,338,93,338,76,338,87,338,58,9.69,8.38,0.89,0.754,1.051,Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,50.74,2010,Lynch TJ and Patel T and Dreisbach L and McCleod M and Heim WJ and Hermann RC and Paschold E and Iannotti NO and Dakhil S and Gorton S and Pautret V and Weber MR and Woytowitz D,Lynch,https://pubmed.ncbi.nlm.nih.gov/20100966/,20100966,0.064795918,0.078571429,0.849223947,-0.16343235,0.120894248,0.104704584,0.085502519,0.060483977,0.027136988,1.308592911,0.922548684,1.856178906,1.673306773,1.151905207,2.430716989,0.238170975,0.326227495,0.782040049,-0.245849326,0.260960024,0.226079665,0.184726545,0.130903696,0.059542275
1487,Inclusion,Unclear,Central,Investigator + Central,Investigator + Central,Unclear,Phase 3,NCT00191243,No name,Breast cancer,Breast cancer,Industry,Eli Lilly,2,1,1,docetaxel alternating with gemcitabine,Chemotherapy,docetaxel,Chemotherapy,TTF,RECIST 1.0,122,115,25,NA,NA,NA,1.05,0.79,1.41,122,67,114,69,122,92,114,96,27,28,1.11,0.75,1.64,Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.,Annals of oncology : official journal of the European Society for Medical Oncology,51.77,2010,Joensuu H and Sailas L and Alanko T and Sunela K and Huuhtanen R and Utriainen M and Kokko R and Bono P and Wigren T and Pyrhﾃｶnen S and Turpeenniemi-Hujanen T and Asola R and Leinonen M and Hahka-Kemppinen M and Kellokumpu-Lehtinen P,Joensuu,https://pubmed.ncbi.nlm.nih.gov/19819914/,19819914,#VALUE!,0.158163265,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,0.794466403,0.473315678,1.333521991,0.575,0.300003559,1.102070258,0.219440386,0.204608852,1.381680701,0.323300658,0.424260873,0.368976106,0.303791779,0.220080721,0.115552527
1509,Inclusion,Investigator + Central,Investigator + Central,Central,Central,Blinding,Phase 3,NCT02987543,PROfound ,Prostate cancer,Prostate cancer,Industry,AstraZeneca and Merck Sharp & Dohme,2,≥2,≥2,Olaparib,Target therapy,prespecified physician’s choice,Hormone therapy,PFS,RECIST 1.1,256,131,"cohort A (12.6/13.2), B (NA)",0.36,0.27,0.47,0.49,0.38,0.63,NA,NA,NA,NA,138,30,67,3,17.5,14.3,0.67,0.49,0.93,Olaparib for Metastatic Castration-Resistant Prostate Cancer,The New England journal of medicine,176.08,2020,"Johann de Bono 1, Joaquin Mateo 1, Karim Fizazi 1, Fred Saad 1, Neal Shore 1, Shahneen Sandhu 1, Kim N Chi 1, Oliver Sartor 1, Neeraj Agarwal 1, David Olmos 1, Antoine Thiery-Vuillemin 1, Przemyslaw Twardowski 1, Niven Mehra 1, Carsten Goessl 1, Jinyu Kang 1, Joseph Burgents 1, Wenting Wu 1, Alexander Kohlmann 1, Carrie A Adelman 1, Maha Hussain 1",Johann,https://pubmed.ncbi.nlm.nih.gov/32343890/,32343890,0.051020408,0.06377551,0.734693878,-0.30830136,0.191384302,0.165860325,0.135614689,0.096296627,0.044479182,#VALUE!,#VALUE!,#VALUE!,5.925925926,1.738262336,20.20212793,#VALUE!,4.710169793,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!
1510,Inclusion,Investigator + Central,Investigator + Central,Investigator + Central,Central,Blinding,Phase 2B,NCT01466660,LUX-Lung 7,Non-small cell lung cancer,Non-small cell lung cancer,Industry,Boehringer Ingelheim,2,1,1,Afatinib,Target therapy,gefitinib,Target therapy,PFS,RECIST 1.1,160,159,27.3,0.78,0.61,0.99,0.73,0.57,0.95,NA,NA,NA,NA,160,112,159,89,27.9,25,0.87,0.66,1.15,"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial",The Lancet. Oncology,54.43,2016,"Keunchil Park 1, Eng-Huat Tan 2, Ken O'Byrne 3, Li Zhang 4, Michael Boyer 5, Tony Mok 6, Vera Hirsh 7, James Chih-Hsin Yang 8, Ki Hyeong Lee 9, Shun Lu 10, Yuankai Shi 11, Sang-We Kim 12, Janessa Laskin 13, Dong-Wan Kim 14, Catherine Dubos Arvis 15, Karl Kölbeck 16, Scott A Laurie 17, Chun-Ming Tsai 18, Mehdi Shahidi 19, Miyoung Kim 20, Dan Massey 19, Victoria Zazulina 19, Luis Paz-Ares 21",Keunchil,https://pubmed.ncbi.nlm.nih.gov/27083334/,27083334,0.096938776,0.096938776,1.068493151,0.066249386,0.179559401,0.155539956,0.127058164,0.08997153,0.040690977,#VALUE!,#VALUE!,#VALUE!,1.835205993,1.157557904,2.909557287,#VALUE!,0.446938618,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!,#VALUE!